SCYNEXIS (SCYX) 10-K 7 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 01, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	SCYNEXIS INC
Entity Central Index Key	1,178,253
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus (Q1,Q2,Q3,FY)	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		13,905,599
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 95,905,897

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 46,985	$ 32,243
Prepaid expenses and other current assets	1,452	703
Assets of discontinued operations, net	0	6,701
Total current assets	48,437	39,647
Other assets	419	25
Deferred offering costs	417	0
Total assets	49,273	39,672
Current liabilities:
Accounts payable	619	426
Accrued expenses	3,149	2,245
Accrued severance and retention costs, current	2,639	0
Deferred revenue, current portion	257	257
Liabilities related to assets of discontinued operations	0	2,420
Total current liabilities	6,664	5,348
Deferred revenue, net of current portion	635	893
Deferred rent	25	0
Total liabilities	$ 7,324	$ 6,241
Commitments and contingencies
Stockholders’ equity:
Preferred stock	$ 0	$ 0
Common stock	14	8
Additional paid-in capital	192,069	150,934
Accumulated deficit	(150,134)	(117,511)
Total stockholders’ equity	41,949	33,431
Total liabilities and stockholders’ equity	$ 49,273	$ 39,672

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	May. 07, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	13,905,599	8,512,103
Common stock, shares outstanding (in shares)	13,905,599	8,512,103		334,068
Preferred shares par value (USD per share)	$ 0.001	$ 0.001	$ 0.001
Preferred shares authorized (in shares)	5,000,000	5,000,000	5,000,000
Preferred shares issued (in shares)	0	0
Preferred shares outstanding (in shares)	0	0

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenue	$ 257	$ 1,256
Operating expenses:
Research and development, net	16,440	8,287
Selling, general and administrative	12,166	7,616
Total operating expenses	28,606	15,903
Loss from operations	(28,349)	(14,647)
Other (income) expense:
Amortization of deferred financing costs and debt discount	0	755
Loss on extinguishment of debt	0	1,389
Interest (income) expense	(11)	48
Derivative fair value adjustment	0	(10,080)
Other expense	0	10
Total other (income):	(11)	(7,878)
Loss from continuing operations before taxes	(28,338)	(6,769)
Income tax benefit	0	1,166
Loss from continuing operations	(28,338)	(5,603)
Income (loss) from discontinued operations, net of tax expense of $0 and $1,166 for the years ended December 31, 2015 and 2014, respectively	(4,285)	1,369
Net loss	(32,623)	(4,234)
Deemed dividend for beneficial conversion feature on Series D-2 preferred stock	0	(909)
Deemed dividend for antidilution adjustments to convertible preferred stock	0	(214)
Accretion of convertible preferred stock	0	(510)
Net loss attributable to common stockholders - basic	(32,623)	(5,867)
Derivative fair value adjustment	0	(10,080)
Net loss attributable to common stockholders - diluted	$ (32,623)	$ (15,947)
Net income (loss) per share attributable to common stockholders - basic
Income (loss) per share, continuing operations, per basic share (in dollars per share)	$ (2.33)	$ (1.28)
Income (loss) per share, discontinued operations, per basic share (in dollars per share)	(0.35)	0.24
Basic (in dollars per share)	(2.68)	(1.04)
Net income (loss) per share attributable to common stockholders - diluted
Income (loss) per share, continuing operations, per diluted share (in dollars per share)	(2.33)	(2.92)
Income (loss) per share, discontinued operations, per diluted share (in dollars per share)	(0.35)	0.23
Diluted (in dollars per share)	$ (2.68)	$ (2.69)
Weighted average common shares outstanding:
Basic (in shares)	12,163,559	5,663,311
Diluted (in shares)	12,163,559	5,937,087

Statements of Operations (Paren

Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Tax effect of discontinued operations	$ 0	$ 1,166

Statement of Changes in Convert

Statement of Changes in Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C-1 Convertible Preferred Stock [Member]	Series C-2 Convertible Preferred Stock [Member]	Series D-1 Convertible Preferred Stock [Member]	Series D-2 Convertible Preferred Stock [Member]
Temporary equity, beginning balance at Dec. 31, 2013					$ 250	$ 4,215	$ 28,121	$ 0	$ 13,500	$ 16,952	$ 24,119
Increase (Decrease) in Temporary Equity [Roll Forward]
Sale of preferred stock											544
Reclassification of warrants issued with preferred stock to derivative liability											(544)
Beneficial conversion feature on sale of preferred stock											909
Beneficial conversion feature for antidilution adjustment						18	153		43
Adjustment of preferred stock to liquidation value	$ (510)					(18)	(153)		(43)		724
Conversion of preferred stock into shares of common stock					(250)	(4,215)	(28,121)		(13,500)	(16,952)	(25,752)
Temporary equity, ending balance at Dec. 31, 2014					0	0	0	0	0	0	0
Stockholders' equity, beginning balance at Dec. 31, 2013	(108,109)	$ 0	$ 5,168	$ (113,277)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,234)			(4,234)
Exercise of stock options	9		9
Stock-based compensation expense (Note 10)	1,201		1,201
Beneficial conversion feature on sale of preferred stock	(909)		(909)
Beneficial conversion feature for antidilution adjustment	(214)		(214)
Adjustment of preferred stock to liquidation value	(510)		(510)
Issuance of common stock from the IPO, net of underwriting discounts and commissions and offering expenses	54,583	6	54,577
Conversion of preferred stock into shares of common stock	88,790	2	88,788
Warrant derivative liability reclassified to additional paid-in capital	2,701		2,701
Exercise of common stock warrants	55		55
Issuance of common stock - ESPP	68		68
Stockholders' equity, ending balance at Dec. 31, 2014	33,431	8	150,934	(117,511)
Increase (Decrease) in Temporary Equity [Roll Forward]
Adjustment of preferred stock to liquidation value	0
Temporary equity, ending balance at Dec. 31, 2015					$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(32,623)			(32,623)
Stock-based compensation expense (Note 10)	3,023		3,023
Issuance of common stock from the IPO, net of underwriting discounts and commissions and offering expenses	38,012	6	38,006
Issuance of common stock - ESPP	106		106
Stockholders' equity, ending balance at Dec. 31, 2015	$ 41,949	$ 14	$ 192,069	$ (150,134)

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (32,623)	$ (4,234)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash component of impairment loss on classification of assets as held for sale	586	0
Gain on insurance recovery	0	(165)
Loss on disposal of Services Business	73	0
Loss on extinguishment of debt	0	1,389
Depreciation	447	1,238
Stock-based compensation expense	3,023	1,201
Amortization of deferred financing costs and debt discount	0	755
Change in fair value of derivative liability	0	(10,080)
Changes in deferred rent	(108)	(187)
Changes in operating assets and liabilities:
Accounts receivable and unbilled services	31	(439)
Prepaid expenses, other assets, and deferred costs	(633)	(490)
Accounts payable and accrued expenses	1,066	1,575
Accrued severance and retention cost obligations	2,639	0
Deferred revenue	954	(35)
Net cash used in operating activities	(24,545)	(9,472)
Cash flows from investing activities:
Proceeds from insurance recovery	0	216
Proceeds from sale of Services Business	2,549	0
Purchase of a security	(300)	0
Payment of security deposit	(74)	0
Purchases of property and equipment	(589)	(704)
Net cash provided by (used in) investing activities	1,586	(488)
Cash flows from financing activities:
Proceeds from public offerings	41,400	62,000
Proceeds from sale of preferred stock	0	544
Repayment of debt	0	(15,000)
Payments of offering costs and underwriting discounts and commissions	(3,805)	(6,875)
Proceeds from employee stock purchase plan issuances	106	68
Proceeds from exercise of stock warrants	0	55
Proceeds from exercise of stock options	0	9
Net cash provided by financing activities	37,701	40,801
Net increase in cash and cash equivalents	14,742	30,841
Cash and cash equivalents, beginning of period	32,243	1,402
Cash and cash equivalents, end of period	46,985	32,243
Supplemental cash flow information:
Cash paid for interest	0	49
Noncash financing and investing activities:
Beneficial conversion feature on sale of Series D-2 preferred stock	0	909
Beneficial conversion feature for antidilution adjustment	0	214
Adjustment of preferred stock to redemption value	0	510
Issuance of warrants allocated to debt discount	0	906
Equipment purchases in accounts payable and accrued expenses	0	34
Impairment of fixed asset	0	51
Deferred offering costs reclassified to additional paid-in capital	3,388	4,126
Warrant derivative liability reclassified to additional paid-in capital	0	2,701
Conversion of convertible preferred stock to common stock	0	88,790
Proceeds from sale of Services Business held in escrow	$ 500	$ 0

Description of Business and Bas

Description of Business and Basis of Preparation	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Preparation	Description of Business and Basis of Preparation Organization SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”) is a Delaware corporation formed on November 4, 1999 . SCYNEXIS is a pharmaceutical company, headquartered in Jersey City, New Jersey committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Until July 17, 2015, the Company also offered its services in drug discovery and development, primarily in the form of integrated research teams consisting of medicinal, computational, analytical, and process scientists working on a collaborative basis with its customers on research projects. These services were provided by the Company's contract research and development services business (the "Services Business") asset group. As part of the Company's strategic objective to focus its resources on the development of SCY-078, the Company's board of directors directed the Company to divest the Services Business, which was no longer strategic to the Company's business. On July 21, 2015, the Company completed the sale of the Services Business asset group pursuant to an Asset Purchase Agreement (the "Purchase Agreement"), with an effective date of July 17, 2015, with Accuratus Lab Services, Inc. ("Accuratus"), a private-equity backed process chemistry, formulation, manufacturing and analytical development services provider. The material terms of the Services Business sale transaction are described in Note 18. Discontinued Operations As described above and more fully in Note 18, the Company completed the sale of the Services Business on July 21, 2015. The accompanying audited financial statements reflect the retrospective adjustments for the periods presented to include the Services Business in discontinued operations pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the accounts receivable allowance; the fair value of the Company’s common stock used to measure stock-based compensation for options granted to employees and nonemployees and to determine the fair value of common stock warrants; the Services Business asset group's fair value less costs to sell, which was used to assess the Services Business asset group for impairment; the fair value of convertible preferred stock; the fair value of the Company’s derivative liability; the estimate of services and effort expended by third-party research and development service providers used to recognize research and development expense; and the estimated useful lives of property and equipment. Reverse Stock-splits On March 17, 2014, the Company amended its amended and restated certificate of incorporation to implement a 1-for-4 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. On April 25, 2014, the Company amended its amended and restated certificate of incorporation to implement an additional 1-for-5.1 reverse stock split of its common stock. The reverse stock split did not cause an adjustment to the par value or the authorized shares of the common stock. As a result of the reverse stock split, the Company further adjusted the share amounts under its employee incentive plans, outstanding options and common stock warrant agreements with third parties. All disclosures of common shares and per common share data in the accompanying financial statements and related notes reflect these two reverse stock splits for all periods presented. Initial Public Offering On May 7, 2014, the Company completed an initial public offering (“IPO”) of its common stock. The Company sold an aggregate of 6,200,000 shares of common stock under the registration statement on Form S-1 declared effective by the SEC on May 2, 2014, at a public offering price of $10.00 per share. Net proceeds were $54,583 , after deducting underwriting discounts and commissions of $3,290 and offering expenses of $4,127 . Upon the completion of the IPO, all outstanding shares of the Company’s convertible preferred stock were automatically converted into 1,691,884 shares of common stock and certain outstanding warrants were exercised for an additional 275,687 shares of common stock. In connection with the consummation of the IPO, the Company repaid outstanding debt with a principal balance of $15,000 , plus all accrued interest, to the holder of such debt, which was outstanding pursuant to a credit agreement referred to herein as the 2013 Credit Agreement. April 2015 Follow-On Public Offering On April 28, 2015, the Company completed a follow-on public offering (the "April 2015 Offering") of its common stock. The Company sold an aggregate of 5,376,622 shares of common stock at a public offering price of $7.70 per share. Net proceeds were approximately $38,012 , after deducting underwriting discounts and commissions and offering expenses of approximately $3,388 . The significant increase in the shares outstanding beginning in April 2015 has impacted the comparability of the Company's net income (loss) per share calculations between the 2015 and 2014 periods. Shelf Registration Filing On October 30, 2015, the Company filed a shelf registration statement on Form S-3 with the SEC which was declared effective on November 16, 2015. The registration statement contained two prospectuses: • a base prospectus which covers the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $150,000 of the Company's common stock, preferred stock, debt securities and warrants, including common stock or preferred stock issuable upon conversion of debt securities, common stock issuable upon conversion of preferred stock, or common stock, preferred stock or debt securities issuable upon the exercise of warrants (the "Shelf Registration"), and • a prospectus covering the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $40,000 of the Company's common stock that may be issued and sold under a sales agreement with Cowen and Company, LLC (the "Sales Agreement Prospectus"). The common stock that may be offered, issued and sold by the Company under the Sales Agreement Prospectus is included in the $150,000 of securities that may be offered, issued and sold by the Company under the base prospectus. Upon termination of the sales agreement with Cowen and Company, LLC, any portion of the $40,000 included in the Sales Agreement Prospectus that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $150,000 of securities may be sold in other offerings pursuant to the base prospectus.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Assets of Discontinued Operations The Company considers assets to be held for sale (i) when management or others having the authority to do so approve a plan to sell the assets, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the assets and writes down the assets to the lower of carrying value or fair market value, if needed. As described in Note 18, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale within the accompanying balance sheets and the results of associated operating activities as discontinued operations within the accompanying statements of operations. Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents held with two banks, which exceed FDIC insured limits, and accounts receivable and unbilled services. Ongoing credit evaluations of customer’s financial condition are performed and independent credit ratings for the associated banks are reviewed by the Company and collateral is not required. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any losses in such deposit account. Revenue recognized from a non-refundable upfront license fee payment received from Waterstone Pharmaceuticals (HK Limited), or Waterstone, a licensing partner (see Note 17), accounted for 0% and 80% of the Company's total revenue in continuing operations for the years ended December 31, 2015 and 2014 , respectively. Revenue recognized from a non-refundable upfront payment from R-Pharm, CJSC (“R-Pharm”), a collaboration partner (see Note 17), accounted for 100% and 20% of the Company's total revenue in continuing operations for the years ended December 31, 2015 and 2014 , respectively. No other parties contributed to the Company's total revenue in continuing operations in 2015 or 2014 . One Services Business customer represented 31% and another customer represented 15% of accounts receivable and unbilled services included in assets of discontinued operations, net at December 31, 2014 . No other Services Business customer accounted for 10% or more of accounts receivable and unbilled services included in assets of discontinued operations, net. One Services Business customer, which was a related-party (see Note 13), accounted for 29% and 41% of the Company’s total revenues in discontinued operations for the years ended December 31, 2015 and 2014 , respectively. Another customer of the Services Business accounted for 23% and 17% of the Company's total revenues in discontinued operations for the year ended December 31, 2015 and 2014 , respectively. No other customer accounted for more than 10% of the Company’s total revenues in discontinued operations in 2015 or 2014 . Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents. Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consisted of amounts billed and unbilled under the Company’s Services Business contracts with its Services Business customers included in assets of discontinued operations, net, in the accompanying balance sheets. The Company extended credit to customers without requiring collateral. Accounts receivable were stated at net realizable value. On a periodic basis, the Company evaluated its accounts receivable and established an allowance based on its history of collections and write-offs and the current status of all receivables. The Company did not accrue interest on trade receivables. Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the respective assets, which generally range from three to seven years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Maintenance and repairs are charged against expense as incurred. Other Assets Other assets consist primarily of the refundable long-term deposit on the leased building facility and the restricted cash posted as collateral for the Company's corporate credit card program. These long term deposits and restricted cash outflows are presented as investing activities within the accompanying statements of cash flows. Deferred Offering Costs Deferred offering costs are expenses directly related to the IPO, the April 2015 Offering, or the Company's shelf registration statement on Form S-3 filed with the SEC in October 2015 (the "Shelf Registration") (see Note 1). These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 Offering were offset against the proceeds from the April 2015 Offering and were reclassified to additional paid-in capital upon completion of the April 2015 Offering. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis in the event the Company completes an offering under the Shelf Registration, with any remaining deferred offering costs charged to the results of operations at the end of the three-year life of the Shelf Registration. As of December 31, 2015 and 2014 , the amount capitalized as deferred offering costs was $417 and $0 , respectively. Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. To date, no such impairment has occurred. During 2015, an impairment charge of $1,350 was recognized within discontinued operations. No other such impairment has occurred. Revenue Recognition and Deferred Revenue Historically, the Company has derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Services Business that was sold in July 2015 (see Note 18). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) fees are fixed or determinable; and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment as revenue when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive prospective performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods. The Company received a non-refundable upfront payment of $1,500 from R-Pharm in August 2013 which is being recognized over a period of 70 months. The Company recognized revenue in continuing operations from this upfront payment of $257 and $256 for the years ended December 31, 2015 and 2014 , respectively. The Company received a non-refundable upfront payment of $500 in January 2014 under a research services agreement supported by the Services Business, which was being recognized over a period of 48 months. The Company recognized revenue in discontinued operations from this upfront payment of $68 and $122 for the years ended December 31, 2015 and 2014 , respectively. Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company has concluded that the August 2013 development, license, and supply agreement with R-Pharm, combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. This agreement and supplemental arrangement is further described in Note 17. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. Unpaid reimbursement amounts due from R-Pharm at period end are presented as an other current asset in the accompanying balance sheets. Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were made under the collaboration arrangement with R-Pharm, which is further described in Note 17. Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the years ended December 31, 2015 and 2014 is presented as follows: Years Ended December 31, 2015 2014 Research and development expense, gross $ 17,380 $ 8,513 Less: Reimbursement of research and development expense 940 226 Research and development expense, net of reimbursements $ 16,440 $ 8,287 Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain. Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances. Amortization of Deferred Financing Costs and Debt Discount Amortization of deferred financing costs and debt discount includes the amortization of debt discount related to the warrants issued with the convertible notes (see Note 6), the amortization of issuance costs related to the convertible notes, and amortization of the deferred financing costs related to a deemed contribution for a guarantee from a related party. Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss. Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period. Certain modifications made to an outstanding incentive stock option award at any time after the initial grant dates which are considered to be “material modifications”, as defined within the Internal Revenue Code, may result in the affected award being recharacterized as a non-statutory stock option. The effects of any recharacterization modification for purposes of income tax accounting are recognized on a prospective basis. Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods. The Company estimated the fair value of common stock warrants granted to lenders at their intrinsic value, which was the estimated fair value of the common stock less the exercise price for the warrant. Deferred Rent The Company recognizes rent expense on a straight-line basis over the non-cancelable term of its operating lease and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. The Company also records landlord-funded lease incentives, such as reimbursable leasehold improvements, as a deferred rent liability, which is amortized as a reduction of rent expense over the non-cancelable term of its operating lease. Basic and Diluted Net Loss per Share of Common Stock The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the SCYNEXIS Board of Directors (the "board of directors" or the "board"), that were made to common stockholders, and as a result were considered participating securities. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period. Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. All assets of the Company were held in the United States for the years ended December 31, 2015 and 2014 . Although all operations are based in the United States, the Company generated a portion of its revenue, including revenue in discontinued operations, from customers outside of the United States. All of the Company's revenue from continuing operations was generated from non-refundable upfront payments received under certain licensing and collaboration arrangements with partners located in Russia and China. Information about the Company’s revenue, including revenue in continuing operations and discontinued operations, from different geographic regions for the years ended December 31, 2015 and 2014 is presented as follows: Years Ended December 31, 2015 2014 United States $ 6,931 90 % $ 16,422 86 % Europe 477 7 % 1,235 7 % Other non-US 257 3 % 1,367 7 % Total revenue 7,665 100 % 19,024 100 % Less: Revenue from discontinued operations 7,408 97 % 17,768 93 % Revenue from continuing operations $ 257 3 % $ 1,256 7 % All sales, including sales outside of the United States, are denominated in United States dollars. Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying financial statements for presentation and disclosure of the Services Business as discontinued operations (see Note 18). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , or ASU 2015-03. Under ASU 2015-03, the costs of issuing debt will no longer be recorded as an intangible asset, except when incurred before receipt of the funding from the associated debt liability. Rather, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The costs will continue to be amortized to interest expense using the effective interest method. ASU 2015-03 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. ASU 2015-03 requires retrospective application to all prior periods presented in the financial statements. The Company does not expect that the adoption of ASU 2015-03 will have a material impact on its financial statements. In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement , or ASU 2015-05 . ASU 2015-05 provides guidance to entities about whether a cloud computing arrangement includes a software license. Under ASU 2015-05, if a software cloud computing arrangement contains a software license, entities should account for the license element of the arrangement in a manner consistent with the acquisition of other software licenses. If the arrangement does not contain a software license, entities should account for the arrangement as a service contract. ASU 2015-05 also removes the requirement to analogize to ASC 840-10, to determine the asset acquired in a software licensing arrangement. For public companies, ASU 2015-05 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is perm

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following: December 31, 2015 2014 Prepaid SCY-078 development services $ 108 $ 109 Prepaid insurance 285 295 Other prepaid expenses 91 70 Other receivable due from R-Pharm 430 226 Escrow receivable due from Accuratus (Note 18) 500 — Other current assets 38 3 Total $ 1,452 $ 703

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following: December 31, 2015 2014 Equipment $ 42 $ 8,552 Furniture and fixtures — 375 Leasehold improvements — 13,193 Total property and equipment 42 22,120 Less accumulated depreciation — 17,285 Property and equipment, net of accumulated depreciation 42 4,835 Property and equipment reclassified to assets of discontinued operations, net — 4,835 Property and equipment, net of assets of discontinued operations $ 42 $ — Depreciation expense was $447 and $1,238 for the years ended December 31, 2015 and 2014 , respectively, including $391 and $1,132 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2015 and 2014 , respectively. As discussed in Note 18, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015, and as a result, the Company stopped recording depreciation expense on that date and assessed the property and equipment assets for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . See Note 16 for the Company's impairment assessment of the Service Business asset group and the resulting impairment charge. In the quarter ended June 30, 2014, the Company’s insurance carrier remitted proceeds for the replacement cost of a fixed asset that was damaged by severe weather. The asset’s net book value was reduced upon occurrence of the damage. The proceeds received from the insurance recovery exceeded the net book value of the asset by $165 , which was recognized as a gain during the quarter ended June 30, 2014. The replacement asset was delivered, installed and placed in service during the quarter ended September 30, 2014. The fixed asset, and the resulting gain, was directly related to the Services Business and, therefore, is presented in discontinued operations in the accompanying statements of operations.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consist of the following: December 31, 2015 2014 Accrued research and development expenses $ 1,903 $ 293 Accrued employee bonus compensation 776 1,464 Employee withholdings 42 156 Other accrued expenses 428 332 Total accrued expenses $ 3,149 $ 2,245 Severance Costs In June 2014, the Company reduced its workforce in an effort to reduce operating costs. Employee severance costs associated with this action were $379 , which were expensed in the quarter ended June 30, 2014. In 2015, the Company entered into certain compensatory arrangements and commitments with employees and officers, including severance and retention obligations, the material terms of which are described in Note 15.

Debt Obligations

Debt Obligations	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Obligations	Debt Obligations Credit Facility Agreement In April 2010, the Company entered into a $15,000 credit facility agreement with HSBC Bank (the “2010 Credit Agreement”). The agreement comprised a $5,000 term loan and a $10,000 revolving credit facility. Borrowings under the 2010 Credit Agreement carried interest at a rate of London InterBank Offered Rate plus 0.95% per annum. The 2010 Credit Agreement required interest-only payments through March 2013 and was guaranteed by a related party that has an investment in the Company. All outstanding borrowings under the agreement were originally due on March 11, 2013. The 2010 Credit Agreement contained no financial covenants. At the inception of the 2010 Credit Agreement, a deemed contribution in relation to the guarantee of the 2010 Credit Agreement was recognized as deferred financing costs and amortized over the life of the loan. The value of the guarantee was determined based on the difference between the loan’s stated interest rate and the interest rate that would apply if there had been no guarantee from the related party. The Company determined the value of the 2010 Credit Agreement guarantee to be $6,338 , which was amortized over the original life of the loan. On March 8, 2013, the Company entered into an agreement to amend the 2010 Credit Agreement with HSBC Bank (the “2013 Credit Agreement”). The 2013 Credit Agreement required interest-only payments through December 2014 when all outstanding borrowings were due. Other significant terms of the 2010 Credit Agreement remained the same, which included the guarantee made by a related party that has an investment in the Company. The 2013 Credit Agreement represented a new loan, and the Company determined the value of the extended guarantee under the 2013 Credit Agreement to be $3,930 , which was amortized over the term of the 2013 Credit Agreement. Pursuant to an addendum dated April 29, 2014, upon completion of the IPO on May 7, 2014, the entire outstanding balance of the 2013 Credit Agreement, amounting to $15,000 plus accrued interest, was paid in full using the proceeds from the IPO. The payment on May 7, 2014, released the related party guarantor from all obligations under and in relation to the 2013 Credit Agreement. The Company recorded a loss on the extinguishment of debt of $1,389 in the three month period ended June 30, 2014 as the remaining deferred financing costs associated with the 2013 Credit Agreement were written off. The Company had no outstanding debt as of December 31, 2015 . Amortization of deferred financing costs associated with the 2010 Credit Agreement and 2013 Credit Agreement was $0 and $755 for the years ended December 31, 2015 and 2014 , respectively. The weighted-average interest rate was 0.00% and 1.19% for the years ended December 31, 2015 and 2014 , respectively. Interest expense was $0 and $48 for the years ended December 31, 2015 and 2014 , respectively. Note and Warrant Purchase Agreements In December 2011, the Company executed a Note and Warrant Purchase Agreement (the “December 2011 Note and Warrant Agreement”) to issue convertible notes in an aggregate amount not to exceed $15,000 . In 2011 and 2012, under the December 2011 Note and Warrant Agreement, the Company issued convertible notes (the “2011-2012 Notes”) with a total principal amount of $11,444 to related parties that held investments in the Company. The 2011-2012 Notes included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The 2011-2012 Notes were convertible into shares of the Company’s stock under various methods as stipulated in the agreement. In June 2013, the Company executed another Note and Warrant Purchase Agreement (the “June 2013 Note and Warrant Agreement”) with certain existing lenders. Under the June 2013 Note and Warrant Agreement, the lenders agreed to loan to the Company up to $1,500 in exchange for convertible notes (the “June 2013 Notes”). The Company issued June 2013 Notes for an aggregate amount of $899 . In addition, the Company agreed to issue warrants to purchase shares of the Company’s common stock upon the request of a majority of the noteholders. The June 2013 Notes were convertible into shares of the Company’s stock using methods described in the agreement. In addition, the June 2013 Notes included conversion of the entire outstanding principal and interest balance into equity securities upon the closing of any equity financing at the option of the noteholders. On December 11, 2013, the noteholders elected to convert the June 2013 Notes into shares of Series D-2 convertible preferred stock. Also on December 11, 2013, the noteholders elected to convert the 2011-2012 Notes into shares of Series D-1 and Series D-2 convertible preferred stock. There was no outstanding principal or accrued interest associated with the 2011-2012 Notes and June 2013 Notes as of December 31, 2015 and as of December 31, 2014.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases The Company has relocated its corporate headquarters and operating activities to Jersey City, New Jersey and leases its headquarters facilities under a long-term non-cancelable operating lease. On July 13, 2015, the Company entered into a sublease (the "Sublease") that became effective July 22, 2015, to sublet certain premises consisting of 10,141 square feet of space (the "Subleased Premises") located at 101 Hudson Street, Jersey City, New Jersey from Optimer Pharmaceuticals, Inc. The term of the Sublease commenced on August 1, 2015 (the "Commencement Date") and is scheduled to expire on July 30, 2018. No base rent was due under the Sublease until one month after the Commencement Date. Under the Sublease, the Company is obligated to pay monthly base rent of approximately $25 per month, which amount increases by 3% annually on each anniversary of the Commencement Date. In addition, the Company was required to fund a security deposit with the sublandlord in the amount of $74 . Pursuant to the Purchase Agreement, Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina and the Company was released from any and all post-closing liability under the Durham, North Carolina facility operating lease (see Note 18). Rent expense was approximately $641 and $952 for the years ended December 31, 2015 and 2014 , respectively, including $394 and $827 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2015 and 2014 , respectively. Future minimum lease payments for all operating leases as of December 31, 2015 are as follows: 2016 $ 304 2017 307 2018 182 2019 — 2020 — Thereafter — Total $ 793 License Arrangements with Potential Future Expenditures As of December 31, 2015 , the Company had a license arrangement with Merck Sharp & Dohme Corp., or Merck, as amended, that involves potential future expenditures. Under the license arrangement, the Company exclusively licensed from Merck its rights to SCY-078 in the field of human health. SCY-078 is the Company's lead product candidate. Pursuant to the terms of the license agreement, Merck is eligible to receive milestone payments from the Company that could total $19,000 upon occurrence of specific events, including initiation of a phase 3 clinical study, new drug application, and marketing approvals in each of the U.S., major European markets and Japan. In addition, Merck is eligible to receive tiered royalties from the Company based on a percentage of worldwide net sales of SCY-078. The aggregate royalties are mid- to high-single digits. In December 2014, the Company and Merck entered into an amendment to the license agreement that defers the remittance of a milestone payment due to Merck, such that no amount will be due upon initiation of the first phase 2 clinical trial of a product containing the SCY-078 compound (the "Deferred Milestone"). The amendment also increases, in an amount equal to the Deferred Milestone, the milestone payment that will be due upon initiation of the first Phase 3 clinical trial of a product containing the SCY-078 compound. Except as described above, all other terms and provisions of the license agreement remain in full force and effect. The Company has two additional licensing agreements for other compounds that could require it to make payments of up to $2,300 upon achievement of certain milestones by the Company. Clinical Development Arrangement The Company has entered into, and expects to continue to enter into, contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice. Other Arrangements The Company entered into an agreement with a third party firm to assist the Company in exploring the divestiture of its Services Business (see Note 18). Pursuant to the terms of the agreement, in the event that the Company was able to complete a divestiture of its Services Business to a third-party, the Company was obligated to pay a success fee to the third party firm for the greater of $500 or 4% of the transaction consideration. As described in Note 18, the Company completed the sale of the Services Business pursuant to the Purchase Agreement, dated July 17, 2015. The Company paid and expensed an initial retainer of $50 prior to the closing of the Service Business sale transaction. In July 2015, the Company paid the $450 remaining success fee to the third-party firm in connection with the closing of the sale transaction. Certain of the Company's employees continued to operate from the Durham facility immediately after the closing for a period of up to six months pursuant to a facility lease agreement between the Company and Accuratus dated July 17, 2015. Under the facility lease agreement, the Company was obligated to pay a monthly license fee of approximately $8 per month. In addition, under a Transition Services Agreement, Accuratus provided accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. In connection with the sale of the Services Business, the Company and Accuratus also entered into a Commitment to Services Agreement (the "Services Agreement") pursuant to which Accuratus will provide the Company with certain contract research and development services. The material terms of the Services Agreement are described in Note 18. Compensatory Arrangements with Employees and Officers The Company has entered into certain compensatory arrangements and commitments with employees and officers, the material terms of which are described in Note 15.

Preferred Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2015
Temporary Equity Disclosure [Abstract]
Preferred Stock	Preferred Stock Preferred Stock On May 7, 2014, the Company amended and restated its articles of incorporation relating to its approved capital structure. The Company's board of directors has authorized the Company, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock with a par value of $0.001 per share in one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions. The Company's board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by the our stockholders. The Company's board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. There were no shares of preferred stock issued and outstanding as of December 31, 2015 and 2014, respectively. Convertible Preferred Stock The Company issued multiple series of convertible preferred stock between 2000 and January 2014. In March 2014, the Company amended its amended and restated certificate of incorporation to require the automatic conversion of all series of convertible preferred stock into common stock upon the completion of a public offering of common stock with gross proceeds of at least $20,000 . In May 2014, upon completion of the IPO, all outstanding shares of convertible preferred stock were converted into an aggregate of 1,691,884 shares of common stock at their respective conversion prices. Warrants Associated with Convertible Preferred Stock Issuances In July 2006, the Company issued warrants to purchase 196,923 shares of Series C-1 Preferred Stock, which converted into the right to purchase 14,033 shares of common stock in connection with our IPO, however, we refer to these warrants as our Series C-1 Preferred warrants. The Series C-1 Preferred warrants were issued in conjunction with a loan financing agreement with an original exercise price of $3.25 per share of Series C-1 Preferred, which converted into an exercise price of $45.61 per share of common stock in connection with our IPO. These warrants remain outstanding as of December 31, 2015 and will expire on May 7, 2019 , which is the five year anniversary of the Company's IPO. The fair value at the date of grant for these instruments was $459 , which was recorded as a debt discount. The debt discount related to these warrants was fully amortized as of December 31, 2010. The Company determined that the warrants should be recorded as a derivative liability and stated at fair value at each reporting period. The Company recorded other income associated with the fair value adjustment for these warrants of $0 and $37 for the years ended December 31, 2015 and 2014 , respectively. The December 11, 2013 Series D-2 Purchase Agreement included warrants to purchase 87,532 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $4,214 , which was recorded as a discount to the Series D-2 Preferred. The fair value of the warrants was $1,714 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 9, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO. On January 31, 2014, the Company sold 388,641 shares of Series D-2 Preferred to related parties under the Series D-2 Purchase Agreement at $1.40 per share, for an aggregate price of $544 . The sale also included warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. The fair value of the warrants on the date of issuance was $906 . The fair value of the warrants was $362 above the face amount of the Series D-2 Preferred and this excess was expensed to derivative fair value adjustment at issuance. As described in Note 9, the warrants were classified as a derivative liability and were stated at fair value at each reporting period end date prior to being exercised in May 2014 in conjunction with the Company’s IPO.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Common Stock	Common Stock Authorized, Issued, and Outstanding Common Shares The Company’s common stock has a par value of $0.001 per share and consists of 125,000,000 authorized shares as of December 31, 2015 and 2014 , respectively; 13,905,599 and 8,512,103 shares were issued and outstanding as of December 31, 2015 , and December 31, 2014 , respectively. The following table summarizes common stock share activity for the years ended December 31, 2015 and 2014 : Shares of Balance, December 31, 2013 334,068 Exercise of stock options 416 Conversion of preferred stock 1,691,884 Exercise of common stock warrants 275,687 Common stock issued through IPO 6,200,000 Common stock issued through employee stock purchase plan 10,048 Balance, December 31, 2014 8,512,103 Common stock issued through April 2015 Offering 5,376,622 Common stock issued through employee stock purchase plan 16,874 Balance, December 31, 2015 13,905,599 Shares Reserved for Future Issuance The Company had reserved shares of common stock for future issuance as follows: December 31, 2015 2014 Outstanding stock options 1,379,727 615,322 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 10) 552,415 180,610 For possible future issuance under 2014 Employee Stock Purchase Plan (Note 10) 50,283 37,746 For possible future issuance under 2015 Inducement Plan (Note 10) 165,000 — Total common shares reserved for future issuance 2,161,458 847,711 Liquidation Rights In the event of any liquidation or dissolution of the Company, the holders of the common stock are entitled to the remaining assets of the Company legally available for distribution. Dividends and Voting Rights The holders of the common stock are entitled to receive dividends if and when declared by the Company. The holders of the common stock have the right to one vote per share. Common Stock Warrants The Company had outstanding common stock warrants issued in connection with the Note and Warrant Purchase Agreements (Note 6) and in connection with certain convertible preferred stock agreements (Note 8). The December 2011 Note and Warrant Purchase Agreement included warrants to purchase 26,000 shares of the Company’s common stock at $0.20 per share. The warrants could be exercised for shares of common stock, in accordance with their terms. The number of shares of common stock that could be purchased by exercising the warrants would vary based on the event that occurred and would be calculated in accordance with the December 2011 Note and Warrant Purchase Agreements (Note 6). On December 11, 2013, holders of the June 2013 Notes exercised their rights under the June 2013 Note and Warrant Agreement to receive warrants to purchase shares of the Company’s common stock. As a result of this exercise, the Company issued warrants to purchase 88,987 shares of the Company’s common stock to the holders of the June 2013 Notes at an exercise price of $0.20 per share. These warrants were exercisable until June 28, 2018 , and would terminate unless exercised prior to an IPO. On December 11, 2013, in connection with the first Series D-2 Preferred offering, the Company issued warrants to purchase 87,532 shares of the Company’s common stock at an exercise price of $0.20 per share. These warrants were exercisable until December 11, 2018 , and would terminate unless exercised prior to an IPO. In addition, as a result of the conversion of the principal and interest outstanding on the 2011-2012 Notes into Series D-1 Preferred and Series D-2 Preferred (Note 6), in accordance with the amended terms of the agreement, the number of common shares underlying the warrants issued in connection with the 2011-2012 Notes was increased by 54,120 to a total of 80,120 . On January 31, 2014, in connection with the second Series D-2 Preferred offering, the Company issued warrants to purchase 19,048 shares of the Company’s common stock at $0.20 per share. In connection with the consummation of the IPO in May 2014, substantially all outstanding common stock warrants were exercised at an exercise price of $0.20 per share and the holders received 275,687 shares of common stock. All previously described warrants met the definition of a derivative financial instrument and were accounted for as derivatives. The combined fair value of the common stock warrant derivative liabilities, including warrants issued with the sale of Series D-2 Preferred, was $2,701 as of May 2, 2014, and this amount was settled to additional paid in capital on that date. The fair value adjustment of the long-term derivative liability for common stock warrants was recorded as other income in the amount of $10,442 for the year ended December 31, 2014 . As discussed in Note 8, the fair value of the warrants issued in connection with the Company’s Series D-2 Preferred offering in January 2014 was $362 above the face amount of the Series D-2 Preferred. This excess was expensed in the year ended December 31, 2014 , and, as a result, the net fair value adjustment presented in the accompanying statements of operations for the year ended December 31, 2014 , was income of $10,080 .

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based Compensation	Stock-based Compensation 2009 Stock Option Plan The Company had a share-based compensation plan (the “2009 Stock Option Plan”) under which the Company granted options to purchase shares of common stock to employees, directors, and consultants as either incentive stock options or nonqualified stock options. Incentive stock options could be granted with exercise prices not less than 100% to 110% of the fair market value of the common stock. Options granted under the plan generally vest over three to four years and expire in 10 years from the date of grant. 2014 Equity Incentive Plan In February 2014, the Company’s board of directors adopted the 2014 Equity Incentive Plan, or the 2014 Plan, which was subsequently ratified by its stockholders and became effective on May 2, 2014 (the “Effective Date”). The 2014 Plan is the successor to and continuation of the 2009 Stock Option Plan. As of the Effective Date, no additional awards will be granted under the 2009 Stock Option Plan, but all stock awards granted under the 2009 Stock Option Plan prior to the Effective Date will remain subject to the terms of the 2009 Stock Option Plan. All awards granted on and after the Effective Date will be subject to the terms of the 2014 Plan. The 2014 Plan provides for the grant of the following awards: (i) incentive stock options, (ii) nonstatutory stock options, (iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards, and (vi) other stock awards. Employees, directors, and consultants are eligible to receive awards. Under the 2014 Plan, after giving effect to the increases to the share reserve approved by the Company’s stockholders in September 2014, and June 2015, discussed below, the aggregate number of shares of common stock that could be issued from and after the Effective Date (the “share reserve”) could not exceed the sum of (i) 1,122,731 new shares, (ii) the shares that represented the 2009 Stock Option Plan’s available reserve on the Effective Date, and (iii) any returning shares from the 2009 Stock Option Plan. Under the 2014 Plan, the share reserve will automatically increase on January 1 st of each year, for a period of not more than 10 years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to 4.0% of the total number of shares of capital stock outstanding on December 31 st of the preceding calendar year. The board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. On June 18, 2014, the Company’s board of directors and compensation committee approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of the Company’s common stock that may be issued under the 2014 Plan by an additional 351,653 shares. All other material terms of the 2014 Plan remained unchanged. The Company’s stockholders approved the 2014 Plan amendment on September 11, 2014. Pursuant to the terms of the 2014 Plan, on January 1, 2015, the Company automatically added 340,484 shares to the total number shares of common stock available for future issuance under the 2014 Plan. On February 25, 2015, the Company's board of directors approved an amendment of the 2014 Plan, subject to stockholder approval, to increase the aggregate number of shares of common stock that may be issued pursuant to awards under the 2014 Plan by an additional 510,726 shares. The Company's stockholders approved the 2014 Plan amendment on June 4, 2015. All other material terms of the 2014 Plan otherwise remain unchanged. As of December 31, 2015 , there were 552,415 shares of common stock available for future issuance under the 2014 Plan. See Note 19 for certain events occurring after December 31, 2015 that affected the number of shares of common stock available for future issuance under the 2014 Plan. 2015 Inducement Plan On March 26, 2015, the Company's board of directors adopted the 2015 Inducement Plan, or the 2015 Plan. The 2015 Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other forms of equity compensation (collectively, stock awards), all of which may be granted to persons not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to the individuals’ entering into employment with the Company within the meaning of NASDAQ Listing Rule 5635(c)(4). The 2015 Plan has a share reserve covering 450,000 shares of common stock. During the year ended December 31, 2015 , the Company granted options to purchase 285,000 shares of the Company's common stock under to the 2015 Inducement Plan. As of December 31, 2015 , there were 165,000 shares of common stock available for future issuance under the 2015 Plan. Option Valuation Method The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company based its estimated forfeiture rate on historical forfeitures of all stock option grants. The Company has elected to use the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable rather than for use in estimating the fair value of stock options subject to vesting and transferability restrictions. Using the Black-Scholes option-pricing model, the weighted-average fair value of options granted during 2015 and 2014 was $4.79 and $6.24 per option, respectively. The aggregate fair value of options granted during 2015 and 2014 was $4,217 and $3,249 , respectively. The assumptions used to estimate fair value and the resulting grant date fair values are as follows: Employees Nonemployees Years Ended December 31, Years Ended December 31, 2015 2014 2015 2014 Expected dividend yield — — — — Weighted average expected volatility 64.42% 68.57% 63.46% 64.10% Weighted average risk-free interest rate 1.60% 2.05% 1.62% 1.75% Weighted average expected term (in years) 6.07 6.04 5.32 5.30 Forfeiture rate 5.00% 5.00% 5.00% 5.00% The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2015 and 2014 is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding — January 1, 2014 137,610 $ 25.86 5.23 $ 3,097 Granted 520,887 9.53 (1) Exercised (416 ) 20.40 Canceled (42,759 ) 9.57 Outstanding — December 31, 2014 615,322 $ 9.55 9.48 $ 265 Exercisable — December 31, 2014 192,916 $ 9.44 9.48 $ 88 Vested or expected to vest — December 31, 2014 572,926 $ 9.55 9.48 $ 247 Outstanding — January 1, 2015 615,322 $ 9.55 9.48 $ 265 Granted 880,116 $ 8.17 Exercised — $ — Canceled (115,711 ) $ 9.05 Outstanding — December 31, 2015 1,379,727 $ 8.71 7.18 $ — Exercisable — December 31, 2015 635,548 $ 9.41 4.56 $ — Vested or expected to vest —December 31, 2015 1,342,518 $ 8.73 7.11 $ — (1) The weighted average exercise price table takes into consideration the effect of the option award modifications approved by the Company's board of directors on June 18, 2014, and approved by the Company's shareholders on September 11, 2014. These option award modifications are described in further detail below. The intrinsic values in the table above represent the total intrinsic value (the difference between the Company’s closing stock price as of December 31, 2015 and 2014 , and the exercise price multiplied by the number of options). Information as of December 31, 2015 , concerning currently outstanding and vested options is as follows: Outstanding Exercisable Exercise Price Number of Shares Weighted- Average Remaining Contractual Life (in years) Number of Shares Weighted- Average Remaining Contractual Life (in years) $6.53 100,000 9.84 — 0.00 $6.63 21,600 9.95 — 0.00 $6.64 66,563 9.76 6,563 9.76 $6.77 2,166 0.05 2,166 0.05 $6.81 17,400 9.95 — 0.00 $6.89 23,400 9.74 — 0.00 $7.70 5,944 4.88 5,944 4.88 $8.03 5,700 4.80 5,700 4.80 $8.63 26,114 4.79 26,114 4.79 $8.64 8,800 9.56 — 0.00 $8.65 169,000 9.13 8,800 3.73 $8.73 9,000 3.12 4,000 2.66 $8.76 429,198 8.05 93,454 3.84 $8.86 4,941 9.50 4,941 9.50 $9.64 455,069 4.43 450,864 4.39 $9.96 9,326 7.02 9,326 7.02 $10.00 8,316 9.16 486 9.16 $10.81 17,190 8.93 17,190 8.93 Total 1,379,727 Total 635,548 The total fair value of shares vested during the years ended December 31, 2015 and 2014 was $595 and $458 , respectively, which exclude the effects of the 2015 option amendments (described in further detail below) that resulted accelerated vesting and related incremental fair value. Unvested shares as of December 31, 2015 and 2014 are as follows: As of December 31, 2015 As of December 31, 2014 Exercise Price Number of Unvested Shares Exercise Price Number of Unvested Shares $6.53 100,000 $6.53 — $6.63 21,600 $6.63 — $6.64 60,000 $6.64 — $6.77 — $6.77 8,000 $6.81 17,400 $6.81 — $6.89 23,400 $6.89 — $8.64 8,800 $8.64 — $8.65 160,200 $8.65 — $8.73 5,000 $8.73 31,620 $8.76 335,744 $8.76 — $9.64 4,205 $9.64 367,127 $10.00 7,830 $10.00 — $10.81 — $10.81 15,660 Total 744,179 Total 422,407 As of December 31, 2015 and 2014 , there was approximately $2,867 and $2,683 , respectively, of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the plan. That cost is expected to be recognized over weighted-average periods of 3.1 and 3.2 years for the years ended December 31, 2015 and 2014 , respectively. The aggregate intrinsic value of options exercised during the year ended December 31, 2014 was $11 . 2015 Option Amendments During the year ended December 31, 2015 , the following events resulted in the amendment to terms of outstanding stock option awards: • On June 4, 2015, the Company's board of directors approved an extension to the existing 90-day post-employment option exercise period to a period ranging from 36 to 48 months for three directors who resigned from the board effective June 4, 2015. The directors held outstanding options to purchase 48,283 shares of the Company's common stock at a weighted average exercise price of $9.01 per share. All outstanding options were fully vested prior to June 4, 2015. • In connection with the Company's sale of its Services Business (see Note 18), the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting that business (the "Services Business Plan"). The complete terms of the Service Business Plan are described in Note 15. The Company terminated certain employees in June 2015 (the "June 2015 Terminated Employees") who became eligible for severance benefits pursuant to the terms of the Services Business Plan. The outstanding stock options held by the June 2015 Terminated Employees were modified to provide: (i) accelerated vesting of all unvested stock options as of the termination date and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of June 30, 2015, the June 2015 Terminated Employees held outstanding options to purchase 17,715 shares of the Company's common stock at a weighted average exercise price of $9.64 per share, including aggregate unvested options to purchase 8,331 shares at a weighted average exercise price of $9.64 per share. • As described in Note 15, Charles F. Osborne, Jr., the Company’s former chief financial officer, resigned from the Company effective June 30, 2015. The Company's compensation committee of the board of directors approved the following modifications to Mr. Osborne's outstanding options to purchase the Company's common stock: (i) accelerated vesting of all unvested stock options as of June 30, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period to 36 months. As of June 30, 2015, Mr. Osborne held outstanding options to purchase an aggregate of 74,490 shares of the Company's common stock at a weighted average exercise price of $9.53 per share, including unvested options to purchase 50,814 shares at a weighted average exercise price of $9.49 per share. • As described in Note 15, the Company designed a compensatory plan for its non-executive employees in connection with the relocation of its operations to Jersey City, New Jersey (the "Retention Plan"). Pursuant to the terms of the Retention Plan, all stock options held by non-executive employees eligible under the Retention Plan were modified to provide: (i) accelerated vesting of all unvested stock options as of December 31, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of December 31, 2015, the retained employees eligible for participation in the Retention Plan held outstanding options to purchase 96,014 shares of the Company's common stock at a weighted average exercise price of $9.31 per share, including aggregate unvested options to purchase 64,279 shares at a weighted average exercise price of $9.20 per share. • In July 2015, pursuant to the Service Business Plan described in Note 15, the stock options held by each non-executive employee of the Services Business were modified immediately prior to the closing of the sale transaction in July 2015 to provide: (i) accelerated vesting of all unvested stock options as of the closing of the sale transaction and (ii) an extension to the existing 90-day post-employment option exercise period, which varies for each employee based upon years of service, with a maximum exercise period of 48 months. As of July 16, 2015, the non-executive employees of the Services Business held outstanding options to purchase 37,517 shares of the Company's common stock at a weighted average exercise price of $9.62 per share, including aggregate unvested options to purchase 23,052 shares at a weighted average exercise price of $9.61 per share. • On July 21, 2015, Yves J. Ribeill, Ph.D., President and a member of the Company’s board of directors, resigned as President. The Company and Dr. Ribeill entered into a Separation Agreement which included the following modifications to Dr. Ribeill's outstanding options to purchase the Company's common stock: (i) accelerated vesting of all unvested stock options as of July 21, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period to 48 months. As of July 23, 2015, Dr. Ribeill held 84,613 vested options and 183,268 unvested options to purchase shares of the Company’s common stock at a weighted average exercise price of $9.61 and $9.41 per share, respectively. • On September 24, 2015, Edward E. Penhoet, Ph.D. resigned from the Company's board of directors. The Company's board of directors approved the following modifications to Dr. Penhoet's outstanding options to purchase the Company's common stock: (i) accelerated vesting of all unvested stock options as of September 24, 2015, and (ii) an extension to the existing 90-day post-employment option exercise period to 36 months. As of September 24, 2015, Dr. Penhoet held outstanding options to purchase 12,280 shares of the Company's common stock at a weighted average exercise price of $8.64 per share, including aggregate unvested options to purchase 8,800 shares at a weighted average exercise price of $8.65 per share. The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation . The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model to determine an incremental fair value, consistent with and in accordance with the Company’s existing accounting policy for stock compensation (see Note 2). Using the Black-Scholes option-pricing model, the weighted-average incremental fair value of outstanding modified option awards was $3.77 per option share. The total additional compensation cost associated with the previously described modifications was determined to be $1,869 , which was expensed in the year ended December 31, 2015. The remaining additional compensation cost is associated with future service periods and will be recognized as those services are performed. 2014 Option Amendments During the year ended December 31, 2014, the Company's board of directors approved the following with respect to the 2009 Stock Option Plan: • On April 29, 2014, the exercise price per share of certain options to purchase 53,404 shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $10.00 per share. The original exercise prices of such options ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $54.87 per share. • On June 18, 2014, the exercise price per share of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was lowered to an amount equal to $9.64 per share, the closing stock price on June 18, 2014. This modification lowered the exercise price of outstanding options to purchase 110,346 shares of common stock, including those options to purchase common stock that were previously modified on April 29, 2014. These outstanding stock options had exercise prices that ranged from $20.40 to $61.20 per share, with a weighted average exercise price of $41.87 per share. • Also on June 18, 2014, the contractual term of all outstanding options to purchase shares of common stock under the 2009 Stock Option Plan was extended to June 17, 2024. The Company determined the additional compensation cost associated with the previously described modifications pursuant to applicable guidance in FASB ASC Topic 718, Compensation—Stock Compensation . The additional compensation cost was determined by calculating the difference between (a) the estimated fair value of each option award immediately prior to the modifications and (b) the estimated fair value of each option award immediately after the modifications. The fair value of each option award immediately prior to and immediately after modification was estimated using the Black-Scholes option-pricing model, consistent with and in accordance with the Company’s existing accounting policy for stock compensation. Using the Black-Scholes option-pricing model, the weighted-average fair value of outstanding 2009 Stock Option Plan option awards was $3.08 per option immediately prior to modification on June 18, 2014 and was $5.87 per option immediately after modification. The additional compensation cost was determined to be $293 , of which $130 was associated with services previously performed and, therefore, was expensed in the quarter ended June 30, 2014. The remaining additional compensation cost is being recognized as remaining services are performed. Also on June 18, 2014, the board of directors approved modifications to the exercise price and contractual term of all outstanding option awards under the Company’s Stock Option Plan previously adopted by the Company in 1999 (the “1999 Stock Option Plan”). The modifications to the exercise price and contractual term are consistent with those previously described for outstanding options under the 2009 Stock Option Plan. In addition, the 1999 Stock Option Plan option awards were modified to provide that the holder may exercise vested shares under the option for the contractual term of the option even in the event the holder terminates services with the Company other than for cause. The modifications lowered the exercise price of outstanding options to purchase 73,087 shares of common stock, which had exercise prices that ranged from $20.40 to $25.50 per share, with a weighted average exercise price of $21.50 per share. Pursuant to the terms of the 1999 Stock Option Plan, any amendments that modify the terms of the options awards require approval or consent of the Company’s shareholders. No additional compensation cost associated with the options under the 1999 Stock Option Plan was recognized during the quarter ended June 30, 2014 because the amendments were subject to and contingent upon stockholder approval. The Company did not believe stockholder approval was perfunctory. The Company’s stockholders approved the 1999 Stock Option Plan modifications on September 11, 2014, which was considered to be the measurement date for the determination of additional stock compensation expense. Consistent with the accounting guidance and methodology previously described for the 2009 Plan amendment, the Company determined the additional compensation cost associated with the 1999 Stock Option Plan modifications pursuant to FASB ASC Topic 718. The weighted-average fair value of outstanding 1999 Stock Option Plan option awards was $0.78 per option immediately prior to modification on September 11, 2014 and was $3.78 per option immediately after modification. The additional compensation cost was determined to be $225 , all of which was associated with services previously performed and, therefore, was fully expensed in the quarter ended September 30, 2014. 2014 Employee Stock Purchase Plan In February 2014, the Company’s board of directors adopted the 2014 Employee Stock Purchase Plan (“ESPP”), which was subsequently ratified by the Company’s stockholders and became effective on May 2, 2014 . The purpose of the ESPP is to provide means by which eligible employees of the Company and of certain designated related corporations may be given an opportunity to purchase shares of the Company’s common stock, and to seek and retain services of new and existing employees and to provide incentives for such persons to exert maximum efforts for the success of the Company. Common stock that may be issued under the ESPP will not exceed 47,794 shares, plus the number of shares of common stock that are automatically added on January 1 st of each year for a period of ten years, commencing on January 1, 2015 and ending on January 1, 2024, in an amount equal to the lesser of (i) 0.8% of the total number of shares of outstanding common stock on December 31 of the preceding calendar year, and (ii) 29,411 shares of common stock. Similar to the 2014 Plan, the board of directors may act prior to January 1 st of a given year to provide that there will be no increase in the share reserve or that the increase will be a lesser number of shares than would otherwise occur. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code. During the year ended December 31, 2014, the Company issued 10,048 shares of common stock under the ESPP. During the year ended December 31, 2015, the number of shares of common stock available for issuance under the ESPP was automatically increased by 29,411 shares and the Company issued a total of 16,874 shares of common stock under the ESPP. As of December 31, 2015 , there were 50,283 shares of common stock available for future issuance under the ESPP. Compensation Cost The compensation cost that has been charged against income for stock awards under the 2009 Stock Option Plan, the 2014 Plan, and the ESPP was $3,023 and $1,201 for the years ended December 31, 2015 and 2014 , respectively. The total income tax benefit recognized in the statements of operations for share-based compensation arrangements was $0 for both the years ended December 31, 2015 and 2014 . Cash received from options exercised was $0 and $9 for the years ended December 31, 2015 and 2014 , respectively. Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Years Ended December 31, 2015 2014 Research and development $ 300 $ 394 Selling, general and administrative 2,515 648 Discontinued operations 208 159 Total stock-based compensation expense $ 3,023 $ 1,201

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s financial statements include total tax benefit of $0 and $1,166 on net losses from continuing operations before taxes of $28,338 and $6,769 for the years ended December 31, 2015 and 2014 , respectively. Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows: Years Ended December 31, 2015 2014 Amount Percent of Pretax Income Amount Percent of Pretax Income Income taxes from continuing operations at statutory rate $ (9,635 ) 34.0 % $ (2,301 ) 34.0 % State income taxes (196 ) 0.7 % (471 ) 7.0 % Stock warrant derivative liability — — % (3,427 ) 50.6 % Stock-based compensation 15 (0.1 )% 268 (4.0 )% R&D tax credits (1,152 ) 4.1 % (320 ) 4.7 % Loss on sale of discontinued operations, net of reduction in related valuation allowances (1,458 ) 5.1 % — — % Other (127 ) 0.5 % (190 ) 2.8 % Increase (decrease) in valuation allowance 12,553 (44.3 )% 5,275 (77.9 )% Total income tax benefit $ — — % $ (1,166 ) 17.2 % The components of deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows: December 31, 2015 2014 Current deferred tax assets: Accrued expenses $ 783 $ 1,052 Stock-based compensation 1,507 336 Assets of discontinued operations, net of liabilities — 1,882 Other 19 15 2,309 3,285 Noncurrent deferred tax assets (liabilities); Net operating loss carryforwards 42,358 29,981 Research and development credits 3,836 2,684 46,194 32,665 Total deferred tax assets 48,503 35,950 Valuation allowances (48,503 ) (35,950 ) Net deferred tax assets $ — $ — As of December 31, 2015 and 2014 , the Company had available federal net operating loss ("NOL") carryforwards of approximately $117,272 and $81,687 , respectively, North Carolina net economic loss ("NEL") carryforwards of approximately $117,721 and $85,790 , respectively, and Pennsylvania NOL carryforwards of approximately $0 and $0 , respectively. The federal NOL and North Carolina NEL carryforwards begin to expire in 2020 and 2015 , respectively. As of December 31, 2015 , the Company had available federal research and development credit carryforwards of $3,573 and North Carolina credit carryforwards of $255 , which begin to expire in 2020 and 2015 , respectively. As of December 31, 2015 and 2014 , the Company has concluded that it is more likely than not that the Company will not realize the benefit of its deferred tax assets due to its history of losses. Accordingly, the net deferred tax assets have been fully reserved. In accordance with Section 382 of the Internal Revenue Code of 1986, as amended, a change in equity ownership of greater than 50% within a three-year period results in an annual limitation on the Company’s ability to utilize its NOL carryforwards created during the tax periods prior to the change in ownership. The Company has determined that ownership changes have occurred and as a result, a portion of the Company’s NOL carryforwards are limited. Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal and state income tax authorities. The Company adopted FASB Accounting Standards Codification 740-10-25-5, Income Taxes , formerly FASB Interpretation No. 48, Accounting for Uncertainty in Income Taxes , as amended, on January 1, 2009. The difference between the tax benefit recognized in the financial statements and the tax benefit claimed in the tax return is referred to as an unrecognized tax benefit. The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2015 and 2014: December 31, 2015 2014 Unrecognized tax benefit—January 1 $ 623 $ 623 Additions for tax positions of current period — — Additions for tax positions of prior periods — — Other — — Unrecognized tax benefit—December 31 $ 623 $ 623 None of the unrecognized tax benefits would, if recognized, affect the effective tax rate because the Company has recorded a valuation allowance to fully offset federal and state deferred tax assets. The Company has no tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within the coming year. The Company has $0 provided for interest and penalties associated with uncertain tax positions.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Years Ended 2015 2014 Income (loss) attributable to common stock - basic: Loss from continuing operations $ (28,338 ) $ (5,603 ) Deemed dividend for beneficial conversion feature on Series D-2 Preferred — (909 ) Deemed dividend for antidilution adjustments to convertible preferred stock — (214 ) Accretion of convertible preferred stock — (510 ) Loss from continuing operations attributable to common stock - basic (28,338 ) (7,236 ) Income from discontinued operations, net of income tax expense, attributable to common stock - basic (4,285 ) 1,369 Net loss attributable to common stock - basic $ (32,623 ) $ (5,867 ) Income (loss) attributable to common stock - diluted: Loss from continuing operations attributable to common stock - basic $ (28,338 ) $ (7,236 ) Derivative fair value adjustment — (10,080 ) Loss from continuing operations attributable to common stock - diluted (28,338 ) (17,316 ) Income from discontinued operations, net of income tax expense, attributable to common stock - diluted (4,285 ) 1,369 Net loss attributable to common stock - diluted $ (32,623 ) $ (15,947 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 12,163,559 5,663,311 Allocation of common stock warrants as participating securities — 273,776 Weighted-average common shares outstanding - diluted 12,163,559 5,937,087 Income (loss) per share - basic: Continuing operations $ (2.33 ) $ (1.28 ) Discontinued operations $ (0.35 ) $ 0.24 Net loss per share - basic $ (2.68 ) $ (1.04 ) Income (loss) per share - diluted: Continuing operations $ (2.33 ) $ (2.92 ) Discontinued operations $ (0.35 ) $ 0.23 Net loss per share - diluted $ (2.68 ) $ (2.69 ) The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. As discussed in Note 8, in May 2014, upon completion of the IPO, all outstanding shares of the convertible preferred stock were converted into shares of common stock at their conversion prices. Therefore, as of December 31, 2015 , the convertible preferred stock securities were no longer outstanding and will have no impact on net income or net loss per share. Years Ended 2015 2014 Convertible preferred stock: Series A Preferred — 6,149 Series B Preferred — 131,685 Series C Preferred — 783,515 Series C-2 Preferred — 173,213 Series D-1 Preferred — 296,773 Series D-2 Preferred — 300,549 Warrants to purchase Series C-1 Preferred 14,033 14,033 Stock options 1,379,727 615,322 ESPP — 65,401

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions The Company had transactions with related parties as follows: Years Ended December 31, 2015 2014 Revenue $ 2,140 $ 7,288 Selling, general and administrative expense $ — $ 500 Research Services Agreement with a Related-Party Sanofi owns 100% of a subsidiary, Merial, which was a customer of the Services Business, presented in discontinued operations in the accompanying statements of operations (see Note 18). Both Sanofi and the subsidiary have an investment in the Company. The Company’s related-party revenue with Merial composed 29% and 41% of total revenue in discontinued operations for the years ended December 31, 2015 and 2014 , respectively. Success Fee Paid to a Related Party In May 2014, the Company paid a $500 success fee to Burrill Securities, an affiliate of Burrill Biotechnology Capital Fund, L.P., a holder of the Company’s capital stock, pursuant to an engagement letter. The fee was recognized as general and administrative expense in the accompanying statements of operations.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company has a 401(k) retirement plan, which covers all U.S. employees scheduled for and working more than 20 hours per week. The Company may provide a discretionary match with a maximum amount of 50% of the first 6% of eligible participant’s compensation, which vests ratably over four years . Contributions under the plan during were approximately $183 and $239 during the years ended December 31, 2015 and 2014 , respectively, including $104 and $176 presented in discontinued operations in the accompanying statements of operations for the years ended December 31, 2015 and 2014 , respectively.

Compensatory Obligations

Compensatory Obligations	12 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Compensatory Plan Obligations	Compensatory Plan Obligations Compensatory Plan with Services Business Employees In connection with the Company's sale of its Services Business, which is more fully described in Note 18, the Company designed a compensatory plan to promote the retention of services of its non-executive employees supporting that business (the "Services Business Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Services Business Plan prior to June 30, 2015, to all non-executive employees of the Services Business. The Services Business Plan terms provided for certain cash compensation payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below, upon the successful closing of the sale of the Services Business. The sale closed in July 2015 (see Note 18). The Services Business Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations and all related expenses incurred have been presented in discontinued operations in the statements of operations in the period incurred. The Services Business Plan provided that in the event a non-executive employee of the Services Business was not offered a comparable position by Accuratus, the Company would provide severance payments to such employees. The Company terminated certain employees in June 2015 (the "June 2015 Terminated Employees") who became eligible for severance benefits totaling approximately $999 pursuant to the terms of the Services Business Plan, which was expensed in the quarterly period ended June 30, 2015. As of December 31, 2015 , the remaining severance obligation for the June 2015 Terminated Employees was $319 , which was included in accrued severance and retention liabilities in the accompanying balance sheet. The Services Business Plan also provided for certain amendments to the terms of the outstanding stock option awards held by the June 2015 terminated employees, which are described in Note 10. In July 2015, pursuant to the Services Business Plan, the Company paid cash totaling approximately $215 to certain non-executive employees of the Services Business representing an incentive payment upon the closing of the sale of the Services Business. In addition, all non-executive employees of the Services Business were eligible to receive a cash retention compensation payment from the Company on the earlier of (i) the six month anniversary of the closing of the sale transaction, provided that they remained employed by Accuratus as of such date, or (ii) the date of termination of such employee by Accuratus without good cause. Maximum cash retention compensation payments could have totaled approximately $814 under the Services Business Plan, if all service business employees had remained eligible pursuant to the terms of the Services Business Plan. The Company incurred these obligations on the date of the sale of the Services Business in July 2015; therefore, the estimated fair value of the compensation expense associated with these cash payments and obligations was recognized during the quarterly period ended September 30, 2015. As of December 31, 2015 , after adjusting for employees who forfeited their benefits under the Services Business Plan, the Company recorded a liability of $763 , which was included in accrued severance and retention liabilities in the accompanying balance sheet. This liability was satisfied in January 2016 when the Company paid all cash retention compensation payments to the former employees. The Services Business Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in Note 10. Compensatory Arrangement with Employees of the Company's Continuing Operations In connection with the Company's relocation of its continuing operations to Jersey City, New Jersey, the Company designed a compensatory plan to promote the retention of services of non-executive employees supporting its continuing operations (the "Retention Plan"). The Company's board of directors adopted, and the Company communicated, the material terms of the Retention Plan prior to June 30, 2015, to all non-executive employees supporting the Company's continuing operations. The Retention Plan terms provided for certain cash compensation payments and severance payments, as well as modifications to the terms of currently outstanding stock options held by such non-executive employees, as more completely described below. The Company has concluded that the Retention Plan meets the definition of an exit and disposal activity pursuant to FASB ASC 420-- Exit and Disposal Cost Obligations as of June 30, 2015, and all related expenses incurred have been presented in continuing operations in the statements of operations. The Retention Plan provided that non-executive employees were eligible to receive cash bonuses, severance payments and related benefit premiums, provided that all current employees remained employed through December 31, 2015 and were not terminated for cause. The Retention Plan also provided that if the Company and an employee agreed upon a services termination date earlier than December 31, 2015 (the "Release Date"), the employee would remain eligible for all terms of the Retention Plan. The Company accrued this obligation over the remaining future service period required by the employees through the earlier of the Release Date or December 31, 2015. During the year ended December 31, 2015 , the Company recognized total expense of $1,012 , which was included in research and development and selling, general, and administrative expenses in the accompanying statements of operations. The corresponding liability is included in accrued severance and retention obligations in the accompanying balance sheet. The Retention Plan also includes certain amendments to the terms of the eligible employees' outstanding stock option awards, which are described in Note 10. Compensatory Arrangements with Former Executive Officers Charles F. Osborne, Jr., the Company’s former chief financial officer, resigned from the Company effective June 30, 2015. The Company's compensation committee of the board of directors approved a compensatory arrangement for Mr. Osborne that provided for certain payments and benefits, including: (i) a cash payment of approximately $138 upon his resignation on June 30, 2015; (ii) cash severance payments totaling approximately $179 , which was equal to seven months of Mr. Osborne’s then effective base salary, paid over seven months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Mr. Osborne can use towards continuing COBRA premiums for medical, dental, and vision group health coverage for a period up to seven months after the resignation date; and (iv) certain amendments to the terms of Mr. Osborne's outstanding stock option awards (see Note 10). The cash severance payments and related benefit premiums and payroll taxes totaled approximately $335 and were expensed in the quarterly period ended June 30, 2015. As of December 31, 2015 , the remaining obligation of $26 is included in accrued severance and retention liabilities in the accompanying balance sheet. Yves J. Ribeill, Ph.D., President and a member of the Company’s board of directors, resigned as President effective July 21, 2015. Dr. Ribeill continues to serve on the board of directors. The Company and Dr. Ribeill entered into an agreement, effective July 21, 2015, (the “Separation Agreement”), providing for certain payments and benefits to Dr. Ribeill, including: (i) a cash payment of approximately $100 upon the effective date of his resignation; (ii) cash severance payments totaling approximately $900 , paid over 12 months commencing with the first payroll period following the resignation date; (iii) a payment representing a contribution Dr. Ribeill can use towards continuing COBRA premiums for medical, dental, and vision group health coverage after the resignation date; and (iv) certain amendments to the terms of Dr. Ribeill's outstanding stock option awards (see Note 10). The cash severance payments and related benefit premiums and payroll taxes totaled approximately $1,046 as of July 21, 2015, which was recognized as expense in the quarterly period ended September 30, 2015. As of December 31, 2015 , the remaining obligation of $502 is included in accrued severance and retention liabilities in the accompanying balance sheet.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, unbilled services, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis As discussed in Note 18, the Company met the relevant criteria for reporting the Service Business as held for sale on May 4, 2015 (the "Measurement Date"), and as a result, assessed the asset group for impairment pursuant to FASB Topic 360, Property, Plant, and Equipment . The net carrying value of the Services Business asset group was compared to its fair value as of May 4, 2015. The Company determined that the selling price paid by Accuratus to acquire the Services Business asset group was the best estimate of fair value, which the Company concluded was a Level 2 input. The Company determined that the Services Business asset group's net carrying value exceeded its fair value by $572 on the Measurement Date. The Company also estimated selling costs directly attributable to the sale of the Services Business to be $778 . As a result, the Company recorded a $1,350 impairment charge on property and equipment assets classified as held for sale in the quarterly period ended June 30, 2015. The Company subsequently recorded a $73 loss on disposal, after the effects of $764 of actual selling costs, in the quarterly period ended September 30, 2015, due to (i) a difference between estimated and final direct selling costs and (ii) a change in estimated working capital of the Services Business between June 30, 2015 and the effective date of the sale on July 17, 2015. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period, pursuant to the policy described in Note 2. This determination requires significant judgments to be made. The following table summarizes the conclusions reached as of December 31, 2015 and 2014 for financial instruments measured at fair value on a recurring basis: Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2014 Cash on deposit 32,243 32,243 — — Money market funds — — — — Total cash and cash equivalents 32,243 32,243 — — December 31, 2015 Cash on deposit 46,935 46,935 — — Money market funds 50 50 — — Total cash and cash equivalents 46,985 46,985 — — The Company measures cash equivalents at fair value on a recurring basis. The fair value of cash equivalents is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The Company’s derivative liabilities associated with the Series D-2 Preferred sale on January 31, 2014 were measured at fair value on a recurring basis. The fair value of these warrant derivatives was based on a valuation of the Company’s common stock. In order to determine the fair value of the Company’s common stock, the Company used a probability-weighted expected return method, or PWERM. Significant inputs for the PWERM included an estimate of the Company’s equity value, a weighted average cost of capital and an estimated probability and timing for each valuation scenario. A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Year Ended December 31, 2014 Balance - January 1, 2014 $ 12,237 Issuance of warrants 544 Excess of fair value of warrants over proceeds 362 Adjustment to fair value (10,442 ) Reclassification to additional paid-in capital upon exercise of warrants (2,701 ) Balance - December 31, 2014 $ —

Significant Agreements

Significant Agreements	12 Months Ended
	Dec. 31, 2015
Research and Development [Abstract]
Significant Agreements	Significant Agreements R-Pharm Collaboration Arrangement In August 2013, the Company entered into a development, license, and supply agreement (the “original agreement”) with R-Pharm, granting it exclusive rights to develop and commercialize SCY-078, the Company's lead antifungal compound, in the field of human health in Russia and certain smaller non-core markets. The Company received an upfront payment of $1,500 , the unamortized portion of which comprises its deferred revenue balance as of December 31, 2015, and is entitled to receive payments on contingent events, including 1) a development milestone payment of $3,000 upon the first registration of SCY-078 in any country covered by the agreement; 2) sales-based payments of up to $15,000 upon R-Pharm’s achievement of specified targets for cumulative net sales of SCY-078; and 3) percentage royalties of up to the mid-teens on SCY-078 net sales. The Company deferred the upfront payment received and is recognizing it over the estimated relationship period of 70 months, which includes the product development period and an additional period during which the Company is required to participate in a product development committee. The development milestone payment is considered substantive and will be recognized when R-Pharm achieves certain specified milestones. The sales-based payments will not be recognized until the Company 1) receives the payments, and 2) has no continuing performance obligations. If the Company has any continuing performance obligations when the sales-based payments are received, those payments will be deferred and recognized over the remaining period of continuing performance obligations. Royalties will be recognized when payment is received. The original agreement also included terms whereby R-Pharm would reimburse the Company for certain research and development costs associated with Phase 2 and Phase 3 clinical trials of oral SCY-078 and the development of an IV formulation of SCY-078. However, these cost reimbursement terms required that the clinical trials and the IV formulation development follow a global development plan that was agreed upon by both parties in August 2013. Subsequent to August 2013, modifications were made to the global development plan that caused the clinical trial cost reimbursement terms in the original agreement to no longer be enforceable. As a result, the Company concluded that persuasive evidence of a cost reimbursement arrangement did not exist under the original agreement with R-Pharm. Further, the IV formulation development cost reimbursement terms in the original agreement did not specify which IV formulation and development costs were reimbursable by R-Pharm. Because of this lack of specificity, the Company concluded that the reimbursable fees due from R-Pharm were not determinable under the original agreement. In November 2014, the Company entered into a supplemental arrangement with R-Pharm, whereby R-Pharm was informed of the modified IV formulation development plan and R-Pharm agreed to reimburse the Company for specifically identified IV formulation development and manufacturing costs incurred by the Company. The specifically identified costs were defined as all costs incurred by the Company under a separate arrangement between the Company and a third-party service provider, whereby the third-party service provider is performing certain IV formulation and development services. The Company concluded that the original agreement, when combined with the November 2014 supplemental arrangement, provided persuasive evidence of a cost reimbursement arrangement between the Company and R-Pharm as of December 31, 2014. Therefore, the Company has recognized receivables due from R-Pharm and has received reimbursement payments from R-Pharm during 2014 and 2015. The presentation and disclosure associated with this cost reimbursement receivable is in accordance with the Company's research and development expenses accounting policy described in Note 2. The agreement with R-Pharm relates to the Company's continuing operations and was not associated with the sale of the Services Business in July 2015 (see Note 18). Elanco Licensing Agreement The Company entered into a licensing agreement with Elanco Animal Health (Elanco) in December 2013. The Elanco Licensing Agreement is directly related to the Services Business and was assigned to Accuratus in conjunction with the sale of the Services Business in July 2015 (see Note 18), including all future obligations and benefits as summarized below. Revenue from the agreement is included in discontinued operations in the accompanying statements of operations. The agreement included an upfront payment of $500 and multi-year contract research and development services with fees of $2,750 annually for the first two years and $3,000 annually for the second two years , and entitles the Company to 1) development milestone payments of up to $1,500 for each compound Elanco and the Company decided to develop; 2) a one-time payment of up to $2,000 for the first regulatory approval of any product in the U.S.; 3) a one-time payment of $4,000 for the first commercial sale of a product in the U.S. and a one-time payment of $1,500 for the first commercial sale of a product in the European Union; 4) one-time payments of up to $15,000 for reaching specified annual sales of a product; and 5) mid-single-digit percentage royalties on net annual sales. The Company deferred the upfront payment, which it received in January 2014, and was recognizing the revenue over the research and development period of four years . Waterstone Licensing Agreement On October 29, 2014, the Company entered into a license agreement with Waterstone Pharmaceutical (HK Limited), or Waterstone, under which the Company granted Waterstone an exclusive, worldwide license to develop and commercialize SCY-635 for the treatment of viral diseases in humans. In addition, under the same agreement, the Company granted Waterstone an option for an exclusive, worldwide license to develop and commercialize two additional compounds of the Company, SCY-575 and SCY-116, for the treatment of viral diseases in humans. The option is exercisable for a period of 18 months from the date of the agreement. In addition, the Company agreed that during the term of the agreement, it would not develop or commercialize, or grant any right or license to any third party to develop or commercialize, in Asia (excluding Japan), any cyclophilin inhibitor for treatment of viral diseases in humans. The agreement expires upon Waterstone’s last royalty payment, which is the later of ten years from the last registration of the product, or the last to expire of the patents. Either party may terminate the agreement if the other party breaches and fails to remedy the breach after receiving notice from the nonbreaching party. Specifically, the Company has the ability to terminate the agreement if the Company determines that Waterstone failed to make reasonable progress in the development and commercialization of SCY-635 or the optioned compounds. If the Company gives Waterstone notice of failure to make reasonable progress, Waterstone will have the opportunity to correct the deficiencies. If Waterstone fails to do so, the Company has the right to terminate the license. The Company received a non-refundable upfront license fee payment of $1,000 in November 2014 for SCY-635, and may receive an additional upfront payment of $500 if Waterstone exercises its option for the two additional compounds. The Company is also entitled to receive certain payments on contingent future events, including 1) a development milestone payment of $4,000 upon the first registration of a product, and 2) royalties based on a specified percentage of net sales (which percentage is in the mid-single digits), varying based on whether the product contains SCY-635 or one of the two additional compounds. The Company analyzed the license agreement and concluded that, as of December 31, 2014, it had no remaining substantive obligations to perform under the arrangement. As a result, the Company recognized revenue of $ 1,000 from the non-refundable upfront payment in the year ended December 31, 2014. The development milestone payment and the royalties will be recognized as revenue if and when the Company receives the payments. The Waterstone Licensing Agreement relates to the Company's continuing operations and was not associated with the sale of the Services Business in July 2015 (see Note 18). Merial Research Services Agreement In December 2014, the Company entered into an agreement with Merial, a related party (see Note 13), under which the Company provided contract research and screening services in the field of animal health that primarily target parasites. The Merial Research Services Agreement is directly related to the Services Business and was assigned to Accuratus in conjunction with the sale of the Services Business in July 2015 (see Note 18), including all future obligations and benefits as summarized below. Revenue from the agreement is included in discontinued operations in the accompanying statements of operations. Prior to the execution of this agreement, the Company provided contract research and development services for Merial on a fee-for-service basis under a separate agreement that expired on December 31, 2014. The agreement was a non-exclusive arrangement in the animal health field and is on a fee-for-service basis. The Company could not receive any contingent payments based on the progression to development and commercialization of any compounds arising from this agreement. Any intellectual property created in connection the Company's performance of the services would be the sole property of Merial. The term of the agreement was two years, beginning January 1, 2015 and ending on December 31, 2016, and the total service fee due from Merial over the term of the agreement was $7,900 , payable in equal quarterly installments. The agreement also provided for an option to extend the term for one additional year. Either party could terminate the agreement in the event of breach of material obligation by the other party if such breach is not remedied after written notice from the non-breaching party. Either party could terminate this agreement if the other party makes an assignment for the benefit of creditors, becomes subject to bankruptcy proceedings, subject to appointment of a receiver, or admits inability to pay its debts. Further, within six months of any change of control the Company, Merial shall either (i) consent to continue the agreement pursuant to its terms, (ii) agree to an assignment of the agreement to a third-party acceptable to Merial, or (iii) the parties shall implement another solution acceptable to Merial, provided, however, if no resolution acceptable to Merial has been implemented within six months of the change of control, Merial may terminate the agreement immediately. If Merial believes in good faith that the Company acted in any way that may subject Merial to liability under anti-corruption laws, Merial had the unilateral right to terminate this agreement. At termination or expiration of the agreement for any reason, upon Merial’s request, the Company was required to transfer all agreement intellectual property to Merial.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations On May 4, 2015, the Company's board of directors directed management to pursue a plan to sell the Service Business to Accuratus, representing a strategic shift in the Company's operations. The Company met the relevant criteria for reporting the service business as held for sale and in discontinued operations in the second quarter of 2015, pursuant to FASB Topic 205-20, Presentation of Financial Statements--Discontinued Operations , and FASB Topic 360, Property, Plant, and Equipment . The Company assessed the Services Business net asset group for impairment pursuant to FASB Topic 360 and recorded a $1,350 impairment charge on classification of property and equipment assets as held for sale in the quarterly period ended June 30, 2015. The fair value measurement used to determine the impairment charge has been described in Note 16. Sale of the Services Business On July 21, 2015, the Company completed the sale of the Services Business to Accuratus pursuant to the Purchase Agreement, with an effective date of July 17, 2015 for an aggregate purchase price of $3,875 , subject to a working capital adjustment of $824 , which reduced the proceeds at closing. In addition, a portion of the consideration payable at closing equal to $500 was withheld and is subject to an escrow for a period of 12 months from the date of closing to satisfy indemnification obligations of the Company in connection with breaches of any representation and warranties and other customary obligations under the terms of the Purchase Agreement. The Company has not identified any breaches or other events that would cause a reduction in the escrow funds expected to be received by the Company. The escrow funds were recorded as a receivable included in prepaid expenses and other current assets in the accompanying balance sheets. The net cash consideration received by the Company upon closing in July 2015 was $2,549 , after adjusting for the items described above and a nominal escrow fee. The following table describes the net proceeds from the sale and the assets and liabilities sold, net of impairment charges and loss on disposal: July 16, 2015 Net proceeds from sale of the Services Business Net cash consideration received at closing $ 2,549 Consideration in escrow 500 Total consideration 3,049 Less: selling costs 764 Proceeds from sale, net of selling costs $ 2,285 Services Business assets and liabilities disposed of on July 16, 2015 Accounts and unbilled receivables, net $ 1,470 Prepaid expenses and other current assets 713 Property and equipment, net of accumulated depreciation 4,900 Other assets 59 Assets of Services Business, net $ 7,142 Accounts payable and accrued expenses $ 616 Deferred revenue 1,657 Deferred rent 1,161 Liabilities related to assets of the Services Business $ 3,434 Assets of the Services Business, net of liabilities $ 3,708 Less: Impairment charge recognized upon classification as held for sale 1,350 Less: Loss on disposal 73 Assets of the Services Business, net of liabilities and impairment charges $ 2,285 Continuing Involvement with Accuratus As a condition to the execution of the Purchase Agreement, Accuratus assumed the Company’s post-closing obligation under its facility lease in Durham, North Carolina. The Company and its retained employees continued to operate from the Durham facility immediately after the closing for a period of up to 6 months pursuant to a facility lease agreement. In addition, under a Transition Services Agreement, Accuratus provided accounting, IT, payroll, personnel and human resources support, and equity compensation plan administration support services to the Company at rates ranging from one hundred to two hundred dollars per hour for a period of time not to extend beyond December 31, 2015. The Company and Accuratus also entered into the Services Agreement pursuant to which Accuratus will provide the Company with certain contract research and development services for 18 months (the "Initial Term") following the closing of the sale of the Services Business for a minimum purchase obligation of at least $3,300 due from the Company over the Initial Term of the Services Agreement. The purpose of the Services Agreement is to replace services that were previously provided internally by employees of the Company prior to the sale of the Services Business. The employees performing these services became employees of Accuratus in connection with this sale transaction. During the year ended December 31, 2015 , the Company recognized $1,602 of expense for services provided by Accuratus under the Services Agreement, which is included in research and development expense in the accompanying audited statements of operations. Discontinued Operations and Assets Held for Sale The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to assets held for sale, net in the balance sheet: December 31, 2014 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,501 Prepaid expenses and other current assets 289 Property and equipment, net 4,835 Other assets 76 Assets of discontinued operations, net $ 6,701 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 681 Deferred revenue 445 Deferred rent 1,294 Liabilities related to assets of discontinued operations $ 2,420 The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Years Ended December 31, 2015 2014 Major line items constituting income of discontinued operations: Total revenue $ 7,408 $ 17,768 Cost of revenue (7,296 ) (15,446 ) Research and development (860 ) — Selling, general, and administrative — 48 Gain on insurance recovery — 165 Severance and exit costs (Note 15) (2,114 ) — Impairment charge from classification of assets as held for sale (1,350 ) — Gain (loss) on disposal, net of associated transaction costs of $764 (73 ) — Income tax expense — (1,166 ) Income (loss) from discontinued operations, net of income tax expense $ (4,285 ) $ 1,369 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Years Ended December 31, 2015 2014 Depreciation expense $ 391 $ 1,132 Purchases of property and equipment (547 ) (704 ) Proceeds from insurance recovery — 216 Gain on insurance recovery — (165 ) Stock-based compensation 208 159 Changes in deferred rent (133 ) (187 ) Equipment purchases in accounts payable and accrued expenses — 34 Impairment of fixed asset — 51

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Equity Incentive Plan Activities Pursuant to the terms of the 2014 Plan (see Note 10), on January 1, 2016, the Company automatically added 556,223 shares to the total number shares of common stock available for future issuance under the 2014 Plan. Pursuant to the terms of the 2014 ESPP (see Note 10), on January 1, 2016, the Company automatically added 29,411 shares to the total number shares of common stock available for future issuance under the 2014 ESPP.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Assets of Discontinued Operations	Assets of Discontinued Operations The Company considers assets to be held for sale (i) when management or others having the authority to do so approve a plan to sell the assets, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to locate a buyer and other actions required to complete the plan to sell the assets, (iv) consummation of the transaction is probable, (v) the assets are being actively marketed for sale at a price that is reasonable in relation to their current fair value, and (vi) the transaction is expected to qualify for recognition as a completed sale, within one year. Following the classification of property and equipment as held for sale, the Company discontinues depreciating the assets and writes down the assets to the lower of carrying value or fair market value, if needed. As described in Note 18, on May 4, 2015, actions taken by the Company's board of directors caused the Company to meet the relevant criteria for reporting the Services Business as held for sale within the accompanying balance sheets and the results of associated operating activities as discontinued operations within the accompanying statements of operations.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments, which potentially expose the Company to concentrations of credit risk, consist principally of cash on deposit and cash equivalents held with two banks, which exceed FDIC insured limits, and accounts receivable and unbilled services. Ongoing credit evaluations of customer’s financial condition are performed and independent credit ratings for the associated banks are reviewed by the Company and collateral is not required. The Company's money market fund investment (recognized as cash and cash equivalents) is with what the Company believes to be a high quality issuer. The Company has not experienced any losses in such deposit account.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any highly liquid investments with a remaining maturity of three months or less when purchased to be cash and cash equivalents.
Accounts Receivable and Unbilled Services	Accounts Receivable and Unbilled Services Accounts receivable and unbilled services consisted of amounts billed and unbilled under the Company’s Services Business contracts with its Services Business customers included in assets of discontinued operations, net, in the accompanying balance sheets. The Company extended credit to customers without requiring collateral. Accounts receivable were stated at net realizable value. On a periodic basis, the Company evaluated its accounts receivable and established an allowance based on its history of collections and write-offs and the current status of all receivables. The Company did not accrue interest on trade receivables.
Property and Equipment	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined on a straight-line basis over the estimated useful lives of the respective assets, which generally range from three to seven years. Leasehold improvements are amortized over the shorter of the useful life of the asset or the term of the related lease. Maintenance and repairs are charged against expense as incurred.
Other Assets	Other Assets Other assets consist primarily of the refundable long-term deposit on the leased building facility and the restricted cash posted as collateral for the Company's corporate credit card program. These long term deposits and restricted cash outflows are presented as investing activities within the accompanying statements of cash flows.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are expenses directly related to the IPO, the April 2015 Offering, or the Company's shelf registration statement on Form S-3 filed with the SEC in October 2015 (the "Shelf Registration") (see Note 1). These costs consist of legal, accounting, printing, and filing fees that the Company has capitalized, including fees incurred by the independent registered public accounting firm directly related to the offerings. The IPO deferred offering costs were offset against the IPO proceeds in May 2014 and were reclassified to additional paid-in capital upon completion of the IPO. Deferred costs associated with the April 2015 Offering were offset against the proceeds from the April 2015 Offering and were reclassified to additional paid-in capital upon completion of the April 2015 Offering. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis in the event the Company completes an offering under the Shelf Registration, with any remaining deferred offering costs charged to the results of operations at the end of the three-year life of the Shelf Registration.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When such events occur, the Company compares the carrying amounts of the assets to their undiscounted expected future cash flows. If the undiscounted cash flows are insufficient to recover the carrying value, an impairment loss is recorded for the difference between the carrying value and fair value of the asset. To date, no such impairment has occurred.
Revenue Recognition and Deferred Revenue	Revenue Recognition and Deferred Revenue Historically, the Company has derived the majority of its revenue from providing contract research and development services under fee for service arrangements, which were provided by the Services Business that was sold in July 2015 (see Note 18). The Company also has entered into collaboration arrangements in exchange for non-refundable upfront payments and consideration as services are performed. These arrangements include multiple elements, such as the sale of licenses and the provision of services. Under these arrangements, the Company also is entitled to receive development milestone payments and royalties in the form of a designated percentage of product sales. The Company classifies non-refundable upfront payments, milestone payments and royalties received under collaboration and licensing agreements as revenues within its statements of operations because the Company views such activities as being central to its business operations. Revenue is recognized when all of the following conditions are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) fees are fixed or determinable; and (iv) collection of fees is reasonably assured. The Company’s contract research and development services revenue is recognized in the period in which the services are performed. When entering into an arrangement, the Company first determines whether the arrangement includes multiple deliverables and is subject to accounting guidance in ASC subtopic 605-25, Multiple-Element Arrangements . If the Company determines that an arrangement includes multiple elements, it determines whether the arrangement should be divided into separate units of accounting and how the arrangement consideration should be measured and allocated among the separate units of accounting. An element qualifies as a separate unit of accounting when the delivered element has standalone value to the customer. The Company’s arrangements do not include a general right of return relative to delivered elements. Any delivered elements that do not qualify as separate units of accounting are combined with other undelivered elements within the arrangement as a single unit of accounting. If the arrangement constitutes a single combined unit of accounting, the Company determines the revenue recognition method for the combined unit of accounting and recognizes the revenue over the period from inception through the date the last deliverable within the single unit of accounting is delivered. Non-refundable upfront license fees are recorded as deferred revenue and recognized into revenue on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, the Company recognizes non-refundable upfront fees into revenue through the date the deliverable is satisfied. Analyzing the arrangement to identify deliverables requires the use of judgment and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. In arrangements that include license rights and other non-contingent deliverables, such as participation in a steering committee, these deliverables do not have standalone value because the non-contingent deliverables are dependent on the license rights. That is, the non-contingent deliverables would not have value without the license rights, and only the Company can perform the related services. Upfront license rights and non-contingent deliverables, such as participation in a steering committee, do not have standalone value as they are not sold separately and they cannot be resold. In addition, when non-contingent deliverables are sold with upfront license rights, the license rights do not represent the culmination of a separate earnings process. As such, the Company accounts for the license and the non-contingent deliverables as a single combined unit of accounting. In such instances, the license revenue in the form of non-refundable upfront payments is deferred and recognized over the applicable relationship period, which historically has been the estimated period of the Company’s substantive performance obligations or the period the rights granted are in effect. The Company recognizes contingent event-based payments under license agreements when the payments are received. The Company has not received any royalty payments to date. The Company will recognize a milestone payment as revenue when earned if it is substantive and the Company has no ongoing performance obligations related to the milestone. A milestone payment is considered substantive if it: 1) is commensurate with either the Company’s performance to achieve the milestone or the enhanced value of the delivered item as a result of a specific outcome from the Company’s performance to achieve the milestone; 2) relates solely to past performance; and 3) is reasonable relative to all of the deliverables and payment terms, including other potential milestone consideration, within the arrangement. Amounts received prior to satisfying all revenue recognition criteria are recorded as deferred revenue in the accompanying balance sheets. The Company’s deferred revenue includes non-refundable upfront payments received under certain licensing and collaboration arrangements that contain substantive prospective performance obligations that the Company is providing over respective defined service or estimated relationship periods. Such non-refundable upfront payments are recognized over these defined service or estimated relationship periods.
Collaborative Arrangements	Collaboration Arrangements The Company assesses its contractual arrangements, and presents costs incurred and payments received under contractual arrangements, in accordance with FASB ASC 808, Collaborative Arrangements (Topic 808), when the Company determines that the contractual arrangement incudes a joint operating activity, has active participation by both parties, and both parties are subject to significant risks and rewards under the arrangement. When reimbursement payments are due to the Company under a collaborative arrangement within the scope of Topic 808, the Company determines the appropriate classification for each specific reimbursement payment in the statements of operations by considering (i) the nature of the arrangement, (ii) the nature of the Company’s business operations, and (iii) the contractual terms of the arrangement. The Company has concluded that the August 2013 development, license, and supply agreement with R-Pharm, combined with the supplemental arrangement in November 2014, is a collaborative arrangement pursuant to Topic 808 and the Company’s previously described accounting policy. This agreement and supplemental arrangement is further described in Note 17. The reimbursements due from R-Pharm for specified research and development costs incurred by the Company are classified as a reduction to research and development expense in the accompanying statements of operations. The reimbursements due to the Company are recorded as a reduction of expense when (i) the reimbursable expenses have been incurred by the Company, (ii) persuasive evidence of a cost reimbursement arrangement exists, (iii) reimbursable costs are fixed or determinable, and (iv) the collection of the reimbursement payment is reasonably assured. Unpaid reimbursement amounts due from R-Pharm at period end are presented as an other current asset in the accompanying balance sheets.
Research and Development	Research and Development Major components of research and development costs include clinical trial activities and services, including related drug formulation, manufacturing, and other development, preclinical studies, cash compensation, stock-based compensation, fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf, materials and supplies, legal services, and regulatory compliance. The Company is required to estimate its expenses resulting from its obligations under contracts with clinical research organizations, clinical site agreements, vendors, and consultants in connection with conducting SCY-078 clinical trials and preclinical development. The financial terms of these contracts are subject to negotiations which vary from contract to contract, and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company’s objective is to reflect the appropriate development and trial expenses in its financial statements by matching those expenses with the period in which the services and efforts are expended. For clinical trials, the Company accounts for these expenses according to the progress of the trial as measured by actual hours expended by CRO personnel, investigator performance or completion of specific tasks, patient progression, or timing of various aspects of the trial. For preclinical development services performed by outside service providers, the Company determines accrual estimates through financial models, taking into account development progress data received from outside service providers and discussions with applicable Company and service provider personnel. Reimbursements of certain research and development costs by parties under collaborative arrangements have been recorded as a reduction of research and development expense presented within the statement of operations. Such reimbursements were made under the collaboration arrangement with R-Pharm, which is further described in Note 17.
Patent Expenses	Patent Expenses Costs related to filing and pursuing patent applications, as well as costs related to maintaining the Company's existing patent portfolio, are recorded as expense as incurred since recoverability of such expenditures is uncertain.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. The three tiers are defined as follows: • Level 1 — Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; • Level 2 — Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and • Level 3 — Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions about the assumptions market participants would use in pricing the asset or liability based on the best information available in the circumstances.
Amortization of Deferred Financing Costs and Debt Discount	Amortization of Deferred Financing Costs and Debt Discount Amortization of deferred financing costs and debt discount includes the amortization of debt discount related to the warrants issued with the convertible notes (see Note 6), the amortization of issuance costs related to the convertible notes, and amortization of the deferred financing costs related to a deemed contribution for a guarantee from a related party.
Comprehensive Loss	Comprehensive Loss The Company has no items of comprehensive income or loss other than net loss.
Income Taxes	Income Taxes The Company provides for deferred income taxes under the asset and liability method, whereby deferred income taxes result from temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that the Company believes is more likely than not to be realized. The Company recognizes uncertain tax positions when the positions will be more likely than not sustained based solely upon the technical merits of the positions. The Company applies intraperiod tax allocation guidance pursuant to FASB ASC 740, Income Taxes (Topic 740) to allocate income tax (expense) benefit between pre-tax income (loss) from continuing operations and discontinued operations. For periods in which the Company reports pre-tax income from discontinued operations for financial reporting purposes and pre-tax loss from continuing operations, the Company presents income from discontinued operations net of income tax expense attributable to its discontinued operations using the effective tax rate of the Services Business. The Company also recognizes a corresponding income tax benefit on its loss from continuing operations for the same affected period. Certain modifications made to an outstanding incentive stock option award at any time after the initial grant dates which are considered to be “material modifications”, as defined within the Internal Revenue Code, may result in the affected award being recharacterized as a non-statutory stock option. The effects of any recharacterization modification for purposes of income tax accounting are recognized on a prospective basis.
Stock-Based Compensation	Stock-Based Compensation The Company measures and recognizes compensation expense for all stock-based payment awards made to employees, officers, and directors based on the estimated fair values of the awards as of grant date. The Company values equity instruments and stock options granted to employees and non-employee directors using the Black-Scholes valuation model. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods. The Company estimated the fair value of common stock warrants granted to lenders at their intrinsic value, which was the estimated fair value of the common stock less the exercise price for the warrant.
Deferred Rent	Deferred Rent The Company recognizes rent expense on a straight-line basis over the non-cancelable term of its operating lease and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. The Company also records landlord-funded lease incentives, such as reimbursable leasehold improvements, as a deferred rent liability, which is amortized as a reduction of rent expense over the non-cancelable term of its operating lease.
Basic and Diluted Net Loss per Share of Common Stock	Basic and Diluted Net Loss per Share of Common Stock The Company uses the two-class method to compute net loss per share because the Company has issued securities, other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class method requires earnings for the period to be allocated between common stock and participating securities based upon their respective rights to receive distributed and undistributed earnings. Holders of each series of the Company’s convertible preferred stock were entitled to participate in dividends, when and if declared by the SCYNEXIS Board of Directors (the "board of directors" or the "board"), that were made to common stockholders, and as a result were considered participating securities. Under the two-class method, for periods with net income, basic net income per common share is computed by dividing the net income attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Net income attributable to common stockholders is computed by subtracting from net income the portion of current year earnings that the participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss, as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common share is computed under the two-class method by using the weighted average number of shares of common stock outstanding, plus, for periods with net income attributable to common stockholders, the potential dilutive effects of stock options and warrants. In addition, the Company analyzes the potential dilutive effect of the outstanding participating securities when calculating diluted earnings per share. Under the “treasury stock” method, it is assumed that the warrants and options were exercised at the beginning of the period and that the funds obtained from the exercise were used to reacquire the Company’s common stock at the average market price for the period and includes those securities when they are dilutive. Under the “if-converted” method, it is assumed that the outstanding participating securities convert into common stock at the beginning of the period. The Company reports the more dilutive of the approaches as its diluted net income or net loss per share during the period.
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer. The CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. All assets of the Company were held in the United States for the years ended December 31, 2015 and 2014 . Although all operations are based in the United States, the Company generated a portion of its revenue, including revenue in discontinued operations, from customers outside of the United States. All of the Company's revenue from continuing operations was generated from non-refundable upfront payments received under certain licensing and collaboration arrangements with partners located in Russia and China.
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity , or ASU 2014-08. Under ASU 2014-08, only disposals representing a strategic shift in operations that have a major effect on the Company’s operations and financial results should be presented as discontinued operations. Additionally, ASU 2014-08 requires expanded disclosures about discontinued operations that will provide financial statement users with more information about the assets, liabilities, income, and expenses of discontinued operations. The amendments in ASU 2014-08 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. The Company adopted this guidance in the first quarter of 2015 and has applied it in the accompanying financial statements for presentation and disclosure of the Services Business as discontinued operations (see Note 18). The Company will also apply, as applicable, the guidance to future dispositions or classifications as held for sale. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers: Topic 606, or ASU 2014-09. ASU 2014-09 establishes the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. In applying the new revenue recognition model to contracts with customers, an entity: (1) identifies the contract(s) with a customer; (2) identifies the performance obligations in the contract(s); (3) determines the transaction price; (4) allocates the transaction price to the performance obligations in the contract(s); and (5) recognizes revenue when (or as) the entity satisfies a performance obligation. The accounting standards update applies to all contracts with customers except those that are within the scope of other topics in the FASB Accounting Standards Codification. The accounting standards update also requires significantly expanded quantitative and qualitative disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. This guidance is effective for fiscal years and interim periods within those years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of ASU 2014-09 will have on the Company’s financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , or ASU 2014-15. ASU 2014-15 will explicitly require management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Earlier adoption is permitted. The Company is not early adopting ASU 2014-15. The Company is currently evaluating the impact that the implementation of ASU 2014-15 will have on the Company’s financial statements, and the actual impact will be dependent upon the Company’s liquidity and the nature or significance of future events or conditions that exist upon adopting the updated standard. In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , or ASU 2015-03. Under ASU 2015-03, the costs of issuing debt will no longer be recorded as an intangible asset, except when incurred before receipt of the funding from the associated debt liability. Rather, debt issuance costs related to a recognized debt liability will be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The costs will continue to be amortized to interest expense using the effective interest method. ASU 2015-03 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. ASU 2015-03 requires retrospective application to all prior periods presented in the financial statements. The Company does not expect that the adoption of ASU 2015-03 will have a material impact on its financial statements. In April 2015, the FASB issued ASU No. 2015-05, Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement , or ASU 2015-05 . ASU 2015-05 provides guidance to entities about whether a cloud computing arrangement includes a software license. Under ASU 2015-05, if a software cloud computing arrangement contains a software license, entities should account for the license element of the arrangement in a manner consistent with the acquisition of other software licenses. If the arrangement does not contain a software license, entities should account for the arrangement as a service contract. ASU 2015-05 also removes the requirement to analogize to ASC 840-10, to determine the asset acquired in a software licensing arrangement. For public companies, ASU 2015-05 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. The Company does not expect that the adoption of ASU 2015-05 will have a material impact on its financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes , or ASU 2015-17 . ASU 2015-17 provides guidance on balance sheet classification of deferred taxes. The new guidance requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. For public companies, ASU 2015-17 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016, and early adoption is permitted. The Company does not expect that the adoption of ASU 2015-17 will have a material impact on its financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases , or ASU 2016-02 . The new guidance requires lessees to recognize the assets and liabilities arising from leases on the balance sheet. For public companies, ASU 2016-02 is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018, and early adoption is permitted. The Company does not expect that the adoption of ASU 2016-02 will have a material impact on its financial statements.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Research and Development Expenses and Reimbursements	Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the years ended December 31, 2015 and 2014 is presented as follows: Years Ended December 31, 2015 2014 Research and development expense, gross $ 17,380 $ 8,513 Less: Reimbursement of research and development expense 940 226 Research and development expense, net of reimbursements $ 16,440 $ 8,287
Schedule of Segment Reporting Information, by Segment	Information about the Company’s revenue, including revenue in continuing operations and discontinued operations, from different geographic regions for the years ended December 31, 2015 and 2014 is presented as follows: Years Ended December 31, 2015 2014 United States $ 6,931 90 % $ 16,422 86 % Europe 477 7 % 1,235 7 % Other non-US 257 3 % 1,367 7 % Total revenue 7,665 100 % 19,024 100 % Less: Revenue from discontinued operations 7,408 97 % 17,768 93 % Revenue from continuing operations $ 257 3 % $ 1,256 7 %

Prepaid Expenses and Other Cu29

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure	Prepaid expenses and other current assets consist of the following: December 31, 2015 2014 Prepaid SCY-078 development services $ 108 $ 109 Prepaid insurance 285 295 Other prepaid expenses 91 70 Other receivable due from R-Pharm 430 226 Escrow receivable due from Accuratus (Note 18) 500 — Other current assets 38 3 Total $ 1,452 $ 703

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment consists of the following: December 31, 2015 2014 Equipment $ 42 $ 8,552 Furniture and fixtures — 375 Leasehold improvements — 13,193 Total property and equipment 42 22,120 Less accumulated depreciation — 17,285 Property and equipment, net of accumulated depreciation 42 4,835 Property and equipment reclassified to assets of discontinued operations, net — 4,835 Property and equipment, net of assets of discontinued operations $ 42 $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses consist of the following: December 31, 2015 2014 Accrued research and development expenses $ 1,903 $ 293 Accrued employee bonus compensation 776 1,464 Employee withholdings 42 156 Other accrued expenses 428 332 Total accrued expenses $ 3,149 $ 2,245

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Future minimum lease payments for all operating leases as of December 31, 2015 are as follows: 2016 $ 304 2017 307 2018 182 2019 — 2020 — Thereafter — Total $ 793

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Summary of Common Stock Shares Activity	The following table summarizes common stock share activity for the years ended December 31, 2015 and 2014 : Shares of Balance, December 31, 2013 334,068 Exercise of stock options 416 Conversion of preferred stock 1,691,884 Exercise of common stock warrants 275,687 Common stock issued through IPO 6,200,000 Common stock issued through employee stock purchase plan 10,048 Balance, December 31, 2014 8,512,103 Common stock issued through April 2015 Offering 5,376,622 Common stock issued through employee stock purchase plan 16,874 Balance, December 31, 2015 13,905,599
Common Stock Reserved For Future Issuances Table	The Company had reserved shares of common stock for future issuance as follows: December 31, 2015 2014 Outstanding stock options 1,379,727 615,322 Outstanding Series C-1 Preferred warrants 14,033 14,033 For possible future issuance under 2014 Equity Incentive Plan (Note 10) 552,415 180,610 For possible future issuance under 2014 Employee Stock Purchase Plan (Note 10) 50,283 37,746 For possible future issuance under 2015 Inducement Plan (Note 10) 165,000 — Total common shares reserved for future issuance 2,161,458 847,711

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Fair Value Measurement Techniques	The assumptions used to estimate fair value and the resulting grant date fair values are as follows: Employees Nonemployees Years Ended December 31, Years Ended December 31, 2015 2014 2015 2014 Expected dividend yield — — — — Weighted average expected volatility 64.42% 68.57% 63.46% 64.10% Weighted average risk-free interest rate 1.60% 2.05% 1.62% 1.75% Weighted average expected term (in years) 6.07 6.04 5.32 5.30 Forfeiture rate 5.00% 5.00% 5.00% 5.00%
Schedule of Share-based Compensation, Stock Options, Activity	The activity for the 2009 Plan, 2014 Plan and 2015 Plan for the years ended December 31, 2015 and 2014 is summarized as follows: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding — January 1, 2014 137,610 $ 25.86 5.23 $ 3,097 Granted 520,887 9.53 (1) Exercised (416 ) 20.40 Canceled (42,759 ) 9.57 Outstanding — December 31, 2014 615,322 $ 9.55 9.48 $ 265 Exercisable — December 31, 2014 192,916 $ 9.44 9.48 $ 88 Vested or expected to vest — December 31, 2014 572,926 $ 9.55 9.48 $ 247 Outstanding — January 1, 2015 615,322 $ 9.55 9.48 $ 265 Granted 880,116 $ 8.17 Exercised — $ — Canceled (115,711 ) $ 9.05 Outstanding — December 31, 2015 1,379,727 $ 8.71 7.18 $ — Exercisable — December 31, 2015 635,548 $ 9.41 4.56 $ — Vested or expected to vest —December 31, 2015 1,342,518 $ 8.73 7.11 $ — (1) The weighted average exercise price table takes into consideration the effect of the option award modifications approved by the Company's board of directors on June 18, 2014, and approved by the Company's shareholders on September 11, 2014. These option award modifications are described in further detail below.
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	Information as of December 31, 2015 , concerning currently outstanding and vested options is as follows: Outstanding Exercisable Exercise Price Number of Shares Weighted- Average Remaining Contractual Life (in years) Number of Shares Weighted- Average Remaining Contractual Life (in years) $6.53 100,000 9.84 — 0.00 $6.63 21,600 9.95 — 0.00 $6.64 66,563 9.76 6,563 9.76 $6.77 2,166 0.05 2,166 0.05 $6.81 17,400 9.95 — 0.00 $6.89 23,400 9.74 — 0.00 $7.70 5,944 4.88 5,944 4.88 $8.03 5,700 4.80 5,700 4.80 $8.63 26,114 4.79 26,114 4.79 $8.64 8,800 9.56 — 0.00 $8.65 169,000 9.13 8,800 3.73 $8.73 9,000 3.12 4,000 2.66 $8.76 429,198 8.05 93,454 3.84 $8.86 4,941 9.50 4,941 9.50 $9.64 455,069 4.43 450,864 4.39 $9.96 9,326 7.02 9,326 7.02 $10.00 8,316 9.16 486 9.16 $10.81 17,190 8.93 17,190 8.93 Total 1,379,727 Total 635,548
Schedule of Share-based Compensation, Unvested Shares Outstanding, by Exercise Price Range	Unvested shares as of December 31, 2015 and 2014 are as follows: As of December 31, 2015 As of December 31, 2014 Exercise Price Number of Unvested Shares Exercise Price Number of Unvested Shares $6.53 100,000 $6.53 — $6.63 21,600 $6.63 — $6.64 60,000 $6.64 — $6.77 — $6.77 8,000 $6.81 17,400 $6.81 — $6.89 23,400 $6.89 — $8.64 8,800 $8.64 — $8.65 160,200 $8.65 — $8.73 5,000 $8.73 31,620 $8.76 335,744 $8.76 — $9.64 4,205 $9.64 367,127 $10.00 7,830 $10.00 — $10.81 — $10.81 15,660 Total 744,179 Total 422,407
Stock-Based Compensation Expense Related to Stock Options	Stock-based compensation expense related to stock options is included in the following line items in the accompanying statements of operations: Years Ended December 31, 2015 2014 Research and development $ 300 $ 394 Selling, general and administrative 2,515 648 Discontinued operations 208 159 Total stock-based compensation expense $ 3,023 $ 1,201

Income Taxes Income Taxes (Tabl

Income Taxes Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Reconciliations of the differences between the benefit for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows: Years Ended December 31, 2015 2014 Amount Percent of Pretax Income Amount Percent of Pretax Income Income taxes from continuing operations at statutory rate $ (9,635 ) 34.0 % $ (2,301 ) 34.0 % State income taxes (196 ) 0.7 % (471 ) 7.0 % Stock warrant derivative liability — — % (3,427 ) 50.6 % Stock-based compensation 15 (0.1 )% 268 (4.0 )% R&D tax credits (1,152 ) 4.1 % (320 ) 4.7 % Loss on sale of discontinued operations, net of reduction in related valuation allowances (1,458 ) 5.1 % — — % Other (127 ) 0.5 % (190 ) 2.8 % Increase (decrease) in valuation allowance 12,553 (44.3 )% 5,275 (77.9 )% Total income tax benefit $ — — % $ (1,166 ) 17.2 %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred tax assets and liabilities as of December 31, 2015 and 2014 are as follows: December 31, 2015 2014 Current deferred tax assets: Accrued expenses $ 783 $ 1,052 Stock-based compensation 1,507 336 Assets of discontinued operations, net of liabilities — 1,882 Other 19 15 2,309 3,285 Noncurrent deferred tax assets (liabilities); Net operating loss carryforwards 42,358 29,981 Research and development credits 3,836 2,684 46,194 32,665 Total deferred tax assets 48,503 35,950 Valuation allowances (48,503 ) (35,950 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits Roll Forward	The following is a tabular reconciliation of the total amounts of unrecognized tax benefits as of December 31, 2015 and 2014: December 31, 2015 2014 Unrecognized tax benefit—January 1 $ 623 $ 623 Additions for tax positions of current period — — Additions for tax positions of prior periods — — Other — — Unrecognized tax benefit—December 31 $ 623 $ 623

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Income (Loss) Per Share	The following table summarizes the computation of basic and diluted net loss per share attributable to the Company’s common stockholders: Years Ended 2015 2014 Income (loss) attributable to common stock - basic: Loss from continuing operations $ (28,338 ) $ (5,603 ) Deemed dividend for beneficial conversion feature on Series D-2 Preferred — (909 ) Deemed dividend for antidilution adjustments to convertible preferred stock — (214 ) Accretion of convertible preferred stock — (510 ) Loss from continuing operations attributable to common stock - basic (28,338 ) (7,236 ) Income from discontinued operations, net of income tax expense, attributable to common stock - basic (4,285 ) 1,369 Net loss attributable to common stock - basic $ (32,623 ) $ (5,867 ) Income (loss) attributable to common stock - diluted: Loss from continuing operations attributable to common stock - basic $ (28,338 ) $ (7,236 ) Derivative fair value adjustment — (10,080 ) Loss from continuing operations attributable to common stock - diluted (28,338 ) (17,316 ) Income from discontinued operations, net of income tax expense, attributable to common stock - diluted (4,285 ) 1,369 Net loss attributable to common stock - diluted $ (32,623 ) $ (15,947 ) Weighted-average common shares outstanding: Weighted-average common shares outstanding - basic 12,163,559 5,663,311 Allocation of common stock warrants as participating securities — 273,776 Weighted-average common shares outstanding - diluted 12,163,559 5,937,087 Income (loss) per share - basic: Continuing operations $ (2.33 ) $ (1.28 ) Discontinued operations $ (0.35 ) $ 0.24 Net loss per share - basic $ (2.68 ) $ (1.04 ) Income (loss) per share - diluted: Continuing operations $ (2.33 ) $ (2.92 ) Discontinued operations $ (0.35 ) $ 0.23 Net loss per share - diluted $ (2.68 ) $ (2.69 )
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding	The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average common shares outstanding because their effect is anti-dilutive. As discussed in Note 8, in May 2014, upon completion of the IPO, all outstanding shares of the convertible preferred stock were converted into shares of common stock at their conversion prices. Therefore, as of December 31, 2015 , the convertible preferred stock securities were no longer outstanding and will have no impact on net income or net loss per share. Years Ended 2015 2014 Convertible preferred stock: Series A Preferred — 6,149 Series B Preferred — 131,685 Series C Preferred — 783,515 Series C-2 Preferred — 173,213 Series D-1 Preferred — 296,773 Series D-2 Preferred — 300,549 Warrants to purchase Series C-1 Preferred 14,033 14,033 Stock options 1,379,727 615,322 ESPP — 65,401

Related-Party Transactions (Tab

Related-Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Summary of Transactions with Related Parties	The Company had transactions with related parties as follows: Years Ended December 31, 2015 2014 Revenue $ 2,140 $ 7,288 Selling, general and administrative expense $ — $ 500

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The following table summarizes the conclusions reached as of December 31, 2015 and 2014 for financial instruments measured at fair value on a recurring basis: Fair Value Hierarchy Classification Balance Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant unobservable inputs (Level 3) December 31, 2014 Cash on deposit 32,243 32,243 — — Money market funds — — — — Total cash and cash equivalents 32,243 32,243 — — December 31, 2015 Cash on deposit 46,935 46,935 — — Money market funds 50 50 — — Total cash and cash equivalents 46,985 46,985 — —
Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis	A reconciliation of the beginning and ending balances for liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Year Ended December 31, 2014 Balance - January 1, 2014 $ 12,237 Issuance of warrants 544 Excess of fair value of warrants over proceeds 362 Adjustment to fair value (10,442 ) Reclassification to additional paid-in capital upon exercise of warrants (2,701 ) Balance - December 31, 2014 $ —

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2015
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The following table presents a reconciliation of the carrying amounts of assets and liabilities of the Services Business to assets held for sale, net in the balance sheet: December 31, 2014 Carrying amounts of assets included as part of discontinued operations: Accounts and unbilled receivables, net $ 1,501 Prepaid expenses and other current assets 289 Property and equipment, net 4,835 Other assets 76 Assets of discontinued operations, net $ 6,701 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable and accrued expenses $ 681 Deferred revenue 445 Deferred rent 1,294 Liabilities related to assets of discontinued operations $ 2,420 The following table presents revenue, (expenses), gains, and (losses) attributable to discontinued operations: Years Ended December 31, 2015 2014 Major line items constituting income of discontinued operations: Total revenue $ 7,408 $ 17,768 Cost of revenue (7,296 ) (15,446 ) Research and development (860 ) — Selling, general, and administrative — 48 Gain on insurance recovery — 165 Severance and exit costs (Note 15) (2,114 ) — Impairment charge from classification of assets as held for sale (1,350 ) — Gain (loss) on disposal, net of associated transaction costs of $764 (73 ) — Income tax expense — (1,166 ) Income (loss) from discontinued operations, net of income tax expense $ (4,285 ) $ 1,369 The following table presents depreciation, capital expenditures, and significant operating and investing non-cash items related to the discontinued operations: Years Ended December 31, 2015 2014 Depreciation expense $ 391 $ 1,132 Purchases of property and equipment (547 ) (704 ) Proceeds from insurance recovery — 216 Gain on insurance recovery — (165 ) Stock-based compensation 208 159 Changes in deferred rent (133 ) (187 ) Equipment purchases in accounts payable and accrued expenses — 34 Impairment of fixed asset — 51 The following table describes the net proceeds from the sale and the assets and liabilities sold, net of impairment charges and loss on disposal: July 16, 2015 Net proceeds from sale of the Services Business Net cash consideration received at closing $ 2,549 Consideration in escrow 500 Total consideration 3,049 Less: selling costs 764 Proceeds from sale, net of selling costs $ 2,285 Services Business assets and liabilities disposed of on July 16, 2015 Accounts and unbilled receivables, net $ 1,470 Prepaid expenses and other current assets 713 Property and equipment, net of accumulated depreciation 4,900 Other assets 59 Assets of Services Business, net $ 7,142 Accounts payable and accrued expenses $ 616 Deferred revenue 1,657 Deferred rent 1,161 Liabilities related to assets of the Services Business $ 3,434 Assets of the Services Business, net of liabilities $ 3,708 Less: Impairment charge recognized upon classification as held for sale 1,350 Less: Loss on disposal 73 Assets of the Services Business, net of liabilities and impairment charges $ 2,285

Description of Business and B40

Description of Business and Basis of Preparation - Additional Information (Detail)	Oct. 30, 2015USD ($)	Apr. 28, 2015USD ($)$ / sharesshares	May. 07, 2014USD ($)$ / sharesshares	Apr. 25, 2014	Mar. 17, 2014	May. 31, 2014shares	Dec. 31, 2015stock_splitshares	Dec. 31, 2014shares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Reverse stock split ratio, description					1-for-4 reverse stock split
Number of reverse stock splits | stock_split							2
Reverse stock split ratio					0.25
Number of shares of common stock sold (in shares) | shares		5,376,622	6,200,000				5,376,622	6,200,000
Public offering price (in dollars per share) | $ / shares		$ 7.70	$ 10
Net proceeds from initial public offering (IPO) (shares)			$ 54,583,000
Underwriting discounts and commissions			3,290,000
Proceeds from follow-on offering		$ 38,012,000
Offering expenses			$ 4,127,000
Number of outstanding shares of convertible preferred stock converted into common stock (in shares) | shares			1,691,884
Outstanding warrants exercised (in shares) | shares			275,687			275,687		275,687
Payments of stock issuance costs		$ 3,388,000
2013 Credit Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Repayment of debt			$ 15,000,000
Additional Reverse Stock Split [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Reverse stock split ratio, description				1-for-5.1 reverse stock split
Reverse stock split ratio				0.196
Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Maximum aggregate offering price	$ 150,000,000
Common Stock [Member] | Sales Agreement Prospectus [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Maximum aggregate offering price	$ 40,000,000

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Concentration Risk (Details) - Customer Concentration Risk [Member] - customer	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounts Receivable [Member] | Customer Concentration Risk A [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue		31.00%
Number of customers	1
Accounts Receivable [Member] | Customer Concentration Risk B [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue		15.00%
Sales [Member] | Investor [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	29.00%	41.00%
Number of customers	1	1
Sales [Member] | Waterstone Pharmaceuticals [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	0.00%	80.00%
Sales [Member] | R-Pharm, CJSC [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	100.00%	20.00%
Sales [Member] | Customer Concentration Risk F [Member]
Concentration Risk [Line Items]
Percentage of related-party revenue	23.00%	17.00%

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 31, 2014	Aug. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Deferred offering costs			$ 417	$ 0
Impairment charge recognized upon classification as held for sale			1,350
Upfront payment received	$ 500	$ 1,500
Deferred revenue recognition period	48 months	70 months
Revenue recognized from upfront payments			257	256
Recognized upfront payments			$ 68	$ 122
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life			3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment useful life			7 years

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Research and Development Expenses and Reimbursements (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Research and development expense, gross	$ 17,380	$ 8,513
Less: Reimbursement of research and development expense	940	226
Research and development, net	$ 16,440	$ 8,287

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Summary of Revenue, by Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$ 257	$ 1,256
Less: Revenue from discontinued operations	7,408	17,768
Sales Revenue, Net [Member]
Segment Reporting Information [Line Items]
Revenues	$ 7,665	$ 19,024
Percentage of total revenue	100.00%	100.00%
Sales Revenue, Net [Member] | United States [Member]
Segment Reporting Information [Line Items]
Revenues	$ 6,931	$ 16,422
Percentage of total revenue	90.00%	86.00%
Sales Revenue, Net [Member] | Europe [Member]
Segment Reporting Information [Line Items]
Revenues	$ 477	$ 1,235
Percentage of total revenue	7.00%	7.00%
Sales Revenue, Net [Member] | Other Non-US [Member]
Segment Reporting Information [Line Items]
Revenues	$ 257	$ 1,367
Percentage of total revenue	3.00%	7.00%
Revenue from Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Percentage of total revenue	97.00%	93.00%
Continuing Operations [Member]
Segment Reporting Information [Line Items]
Percentage of total revenue	3.00%	7.00%

Prepaid Expenses and Other Cu45

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid SCY-078 development services	$ 108	$ 109
Prepaid insurance	285	295
Other prepaid expenses	91	70
Other receivable due from R-Pharm	430	226
Consideration in escrow	500	0
Other current assets	38	3
Prepaid expenses and other current assets	$ 1,452	$ 703

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 42	$ 22,120
Less accumulated depreciation	0	17,285
Property and equipment, net of accumulated depreciation	42	4,835
Property and equipment reclassified to assets of discontinued operations, net	0	4,835
Property and equipment, net of assets of discontinued operations	42	0
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	42	8,552
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	0	375
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 0	$ 13,193

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense		$ 447	$ 1,238
Proceeds from insurance recovery	$ 165	0	165
Discontinued Operations, Held-for-sale [Member] | Services Business [Member]
Property, Plant and Equipment [Line Items]
Discontinued operations, depreciation expense		391	1,132
Proceeds from insurance recovery		$ 0	$ 165

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued research and development expenses	$ 1,903	$ 293
Accrued employee bonus compensation	776	1,464
Employee withholdings	42	156
Other accrued expenses	428	332
Accrued expenses	$ 3,149	$ 2,245

Accrued Expenses - Additional

Accrued Expenses - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued severance and retention cost obligations	$ 379	$ 2,639	$ 0

Debt Obligations (Detail)

Debt Obligations (Detail) - USD ($)	May. 07, 2014	Mar. 08, 2013	Apr. 30, 2010	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	May. 31, 2014	Jun. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Loss on extinguishment of debt					$ 0	$ 1,389,000
Amortization of deferred financing costs					0	755,000
Interest (income) expense					$ (11,000)	$ 48,000
Number of warrants issued to purchase common stock (in shares)					14,033	14,033
Exercise price of warrants (in dollars per share)							$ 0.20
2010 Credit Agreement [Member]
Debt Instrument [Line Items]
Credit facility agreement amount			$ 15,000,000
Interest at a rate of London InterBank plus			0.95%
Deemed contribution of a loan guarantee			$ 6,338,000
2010 Credit Agreement [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Credit facility agreement amount			5,000,000
2010 Credit Agreement [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Credit facility agreement amount			$ 10,000,000
2013 Credit Agreement [Member]
Debt Instrument [Line Items]
Deemed contribution of a loan guarantee		$ 3,930,000
Repayment of debt	$ 15,000,000
Loss on extinguishment of debt				$ 1,389,000
Debt outstanding					$ 0
Amortization of deferred financing costs					$ 0	$ 755,000
Weighted-average interest rate					0.00%	1.19%
Interest (income) expense					$ 0	$ 48,000
December 2011 Note and Warrant Agreement [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity										$ 15,000,000
2011-2012 Notes [Member] | Convertible Notes Payable [Member] | Investor [Member]
Debt Instrument [Line Items]
Convertible notes aggregate amount									$ 11,444,000	$ 11,444,000
Number of warrants issued to purchase common stock (in shares)										26,000
Exercise price of warrants (in dollars per share)										$ 0.20
June 2013 Note and Warrant Agreement [Member]
Debt Instrument [Line Items]
Debt agreement, maximum borrowing capacity								$ 1,500,000
Convertible notes aggregate amount								$ 899,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jul. 22, 2015USD ($)ft²	Jul. 17, 2015USD ($)	Jul. 31, 2015USD ($)$ / h	Dec. 31, 2015USD ($)Agreement	Dec. 31, 2014USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Payment of security deposit				$ 74,000	$ 0
Rent expense				641,000	952,000
Milestone payments from the Company				$ 19,000,000
Number of additional license agreements | Agreement				2
License agreements fee (up to)				$ 2,300,000
Monthly license fee		$ 8,000
Research and Development Arrangement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Percent of transaction consideration				4.00%
Discontinued Operations [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Rent expense				$ 394,000	$ 827,000
Discontinued Operations, Disposed of by Sale [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Potential success fee payable				$ 500,000
Payment of success fee		$ 50,000	$ 450,000
Discontinued Operations, Disposed of by Sale [Member] | Minimum [Member] | Services Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Employee hourly rate (in dollars per hour) | $ / h			100
Discontinued Operations, Disposed of by Sale [Member] | Maximum [Member] | Services Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Employee hourly rate (in dollars per hour) | $ / h			200
Jersey City, New Jersey [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Sublet premises area (in square feet) | ft²	10,141
Monthly base rent	$ 25,000
Percent increase in base rent annually	3.00%
Payment of security deposit	$ 74,000

Commitments and Contingencies52

Commitments and Contingencies - Future Minimum Lease Payments (Detail) $ in Thousands	Dec. 31, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 304
2,017	307
2,018	182
2,019	0
2,020	0
Thereafter	0
Total	$ 793

Preferred Stock - Additional In

Preferred Stock - Additional Information (Detail) - USD ($)	Jan. 31, 2014	Dec. 11, 2013	May. 31, 2014	Mar. 31, 2014	Jan. 31, 2014	Jul. 31, 2006	Dec. 31, 2015	Dec. 31, 2014	May. 07, 2014
Temporary Equity [Line Items]
Preferred shares authorized (in shares)							5,000,000	5,000,000	5,000,000
Preferred shares par value (USD per share)							$ 0.001	$ 0.001	$ 0.001
Preferred shares issued (in shares)							0	0
Preferred shares outstanding (in shares)							0	0
Automatic conversion trigger (at least)				$ 20,000,000
Conversion of preferred stock (in shares)			1,691,884					1,691,884
Number of warrants issued to purchase common stock (in shares)							14,033	14,033
Exercise price of warrants (in dollars per share)			$ 0.20
Other (expense) income related to fair value adjustment of long term derivative liability								$ 10,442,000
Excess of fair value of warrants over proceeds					$ 362,000			362,000
Proceeds from sale of preferred stock							$ 0	544,000
Series C-1 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)						196,923
Exercise price of warrants (in dollars per share)						$ 3.25
Fair value of warrant on issuance date						$ 459,000
Other (expense) income related to fair value adjustment of long term derivative liability							$ 0	$ 37,000
Common Stock [Member]
Temporary Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)							14,033
Exercise price of warrants (in dollars per share)							$ 45.61
Series D-2 Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)	19,048	87,532			19,048
Exercise price of warrants (in dollars per share)	$ 0.20	$ 0.20			$ 0.20
Fair value of warrant on issuance date	$ 906,000	$ 4,214,000
Excess of fair value of warrants over proceeds	$ 362,000	$ 1,714,000
Temporary equity, shares issued (in shares)	388,641				388,641
Temporary equity issue price per share (in dollars per share)	$ 1.40				$ 1.40
Proceeds from sale of preferred stock	$ 544,000

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	May. 07, 2014	Jan. 31, 2014	Dec. 11, 2013	May. 31, 2014	Jan. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	May. 02, 2014	Dec. 31, 2013	Dec. 31, 2011
Schedule of Capitalization, Equity [Line Items]
Common stock, par value (in dollars per share)						$ 0.001	$ 0.001
Common stock, shares authorized (in shares)						125,000,000	125,000,000
Common stock, shares issued (in shares)						13,905,599	8,512,103
Common stock, shares outstanding (in shares)						13,905,599	8,512,103		334,068
Number of warrants issued to purchase common stock (in shares)						14,033	14,033
Exercise price of warrants (in dollars per share)				$ 0.20
Exercise of common stock warrants (in shares)	275,687			275,687			275,687
Fair value of common stock warrant derivative liabilities								$ 2,701
Adjustment to fair value							$ 10,442
Excess of fair value of warrants over proceeds					$ 362		362
Change in fair value of derivative liability						$ 0	(10,080)
Series D-2 Purchase Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)			87,532
Exercise price of warrants (in dollars per share)			$ 0.20
Increase in the shares of common stock underlying the warrants issued (in shares)			54,120
Revised number of common shares underlying the warrants issued (in shares)			80,120
Series D-2 Convertible Preferred Stock [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)		19,048	87,532		19,048
Exercise price of warrants (in dollars per share)		$ 0.20	$ 0.20		$ 0.20
Excess of fair value of warrants over proceeds		$ 362	$ 1,714
Common Stock Warrant [Member]
Schedule of Capitalization, Equity [Line Items]
Adjustment to fair value							$ 10,442
2011-2012 Notes [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)										26,000
Exercise price of warrants (in dollars per share)										$ 0.20
June 2013 Note and Warrant Agreement [Member]
Schedule of Capitalization, Equity [Line Items]
Number of warrants issued to purchase common stock (in shares)			88,987
Exercise price of warrants (in dollars per share)			$ 0.20

Common Stock - Summary of Commo

Common Stock - Summary of Common Stock Shares Activity (Detail) - shares	Apr. 28, 2015	May. 07, 2014	May. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Common Stock Outstanding Roll Forward [Roll Forward]
Beginning Balance (in shares)				8,512,103	334,068
Exercise of stock options (in shares)				0	416
Conversion of preferred stock (in shares)			1,691,884		1,691,884
Exercise of common stock warrants (in shares)		275,687	275,687		275,687
Common stock issued through IPO (in shares)	5,376,622	6,200,000		5,376,622	6,200,000
Common stock issued through employee stock purchase plan (in shares)				16,874	10,048
Ending Balance (in shares)				13,905,599	8,512,103

Common Stock - Schedule of Rese

Common Stock - Schedule of Reserved Shares of Common Stock for Future Issuance (Detail) - shares	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]
Outstanding stock options (in shares)	1,379,727	615,322	137,610
Outstanding Series C-1 convertible preferred stock warrants (in shares)	14,033	14,033
Total common shares reserved for future issuance (in shares)	2,161,458	847,711
2014 Equity Incentive Plan [Member]
Class of Stock [Line Items]
For possible future issuance under stock option plan (in shares)	552,415	180,610
2014 Employee Stock Purchase Plan [Member]
Class of Stock [Line Items]
For possible future issuance under stock option plan (in shares)	50,283	37,746
2015 Inducement Plan [Member]
Class of Stock [Line Items]
For possible future issuance under stock option plan (in shares)	165,000	0

Stock-based Compensation - 2009

Stock-based Compensation - 2009 Stock Option Plan (Details) - 2009 Stock Option Plan [Member]	12 Months Ended
	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	100.00%
Vesting period of options	3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of exercise price	110.00%
Vesting period of options	4 years

Stock-based Compensation - 2014

Stock-based Compensation - 2014 Equity Incentive Plan (Details) - shares	Jan. 01, 2016	Feb. 25, 2015	Jan. 01, 2015	Jun. 18, 2014	May. 02, 2014	Dec. 31, 2015	Dec. 31, 2014
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Base number of new shares available for future issuance under equity incentive plan					1,122,731
Common stock outstanding percentage					4.00%
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)					0
Aggregate number of shares of the Company's common stock that may be issued (in shares)	556,223	510,726	340,484	351,653
For possible future issuance under stock option plan (in shares)						552,415	180,610
2009 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional awards expected to be granted (in shares)					0
Maximum [Member] | 2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable period					10 years

Stock-based Compensation - 2015

Stock-based Compensation - 2015 Inducement Plan (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 26, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted (in shares)	880,116	520,887
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan (in shares)			450,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	285,000
2015 Inducement Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under stock option plan (in shares)	165,000	0

Stock-based Compensation - Opti

Stock-based Compensation - Option Valuation Method (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Weighted average value of options granted in period (in dollars per share)	$ 4.79	$ 6.24
Aggregate fair value of options	$ 4,217	$ 3,249
Expected dividend yield	0.00%	0.00%
Expected dividend yield, nonemployees	0.00%	0.00%
Weighted average expected volatility	64.42%	68.57%
Weighted average expected volatility, nonemployees	63.46%	64.10%
Weighted average risk-free interest rate	1.60%	2.05%
Weighted average risk-free interest rate, nonemployees	1.62%	1.75%
Weighted average expected term (in years)	6 years 26 days	6 years 15 days
Weighted average expected term (in years), nonemployees	5 years 3 months 26 days	5 years 3 months 17 days
Forfeiture rate	5.00%	5.00%
Forfeiture rate, nonemployees	5.00%	5.00%

Stock-based Compensation - Sto

Stock-based Compensation - Stock-based Compensation Plan Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of Outstanding Stock Options, beginning balance (in shares)	615,322	137,610
Number of Shares Granted (in shares)	880,116	520,887
Number of Shares Exercised (in shares)	0	(416)
Number of Shares Canceled (in shares)	(115,711)	(42,759)
Number of Outstanding Stock Options, ending balance (in shares)	1,379,727	615,322	137,610
Number of Shares Exercisable (in shares)	635,548	192,916
Number of Options Vested and Expected to Vest (in shares)	1,342,518	572,926
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Exercise price, beginning balance (in dollars per share)	$ 9.55	$ 25.86
Weighted Average Exercise Price of Options Granted in Period, per share (in dollars per share)	8.17	9.53
Weighted Average Exercise Price of Options Exercised, per share (in dollars per share)	0	20.40
Weighted Average Exercise Price of Options Canceled, per share (in dollars per share)	9.05	9.57
Weighted Average Exercise Price of Options Exercisable, per share (in dollars per share)	9.41	9.44
Weighted Average Exercise Price of Options Vested and Expected to Vest, per share (in dollars per share)	8.73	9.55
Exercise price, ending balance (in dollars per share)	$ 8.71	$ 9.55	$ 25.86
Weighted- Average Remaining Contractual Life (in years)	7 years 2 months 5 days	9 years 5 months 23 days	5 years 2 months 23 days
Weighted- Average Remaining Contractual Life, Exercisable	4 years 6 months 22 days	9 years 5 months 23 days
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	7 years 1 month 10 days	9 years 5 months 23 days
Aggregate Intrinsic Value	$ 0	$ 265	$ 3,097
Aggregate Intrinsic Value of Options Exercisable	0	88
Aggregate Intrinsic Value of Options Vested and Expected to Vest	$ 0	$ 247

Stock-based Compensation - Ves

Stock-based Compensation - Vested Share-based Compensation, by Exercise Price (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding Number of Shares (in shares)	1,379,727
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	7 years 1 month 10 days	9 years 5 months 23 days
Exercisable Number of Shares (in shares)	635,548
Weighted- Average Remaining Contractual Life, Exercisable	4 years 6 months 22 days	9 years 5 months 23 days
Total fair value of shares vested	$ 595	$ 458
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.53	$ 6.53
Outstanding Number of Shares (in shares)	100,000
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 10 months 2 days
Exercisable Number of Shares (in shares)	0
Weighted- Average Remaining Contractual Life, Exercisable	0 years
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.63	6.63
Outstanding Number of Shares (in shares)	21,600
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 11 months 12 days
Exercisable Number of Shares (in shares)	0
Weighted- Average Remaining Contractual Life, Exercisable	0 years
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.64	6.64
Outstanding Number of Shares (in shares)	66,563
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 9 months 4 days
Exercisable Number of Shares (in shares)	6,563
Weighted- Average Remaining Contractual Life, Exercisable	9 years 9 months 4 days
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.77	6.77
Outstanding Number of Shares (in shares)	2,166
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	18 days
Exercisable Number of Shares (in shares)	2,166
Weighted- Average Remaining Contractual Life, Exercisable	18 days
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.81	6.81
Outstanding Number of Shares (in shares)	17,400
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 11 months 12 days
Exercisable Number of Shares (in shares)	0
Weighted- Average Remaining Contractual Life, Exercisable	0 years
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.89	6.89
Outstanding Number of Shares (in shares)	23,400
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 8 months 27 days
Exercisable Number of Shares (in shares)	0
Weighted- Average Remaining Contractual Life, Exercisable	0 years
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 7.70
Outstanding Number of Shares (in shares)	5,944
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	4 years 10 months 17 days
Exercisable Number of Shares (in shares)	5,944
Weighted- Average Remaining Contractual Life, Exercisable	4 years 10 months 17 days
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.03
Outstanding Number of Shares (in shares)	5,700
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	4 years 9 months 18 days
Exercisable Number of Shares (in shares)	5,700
Weighted- Average Remaining Contractual Life, Exercisable	4 years 9 months 18 days
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.63
Outstanding Number of Shares (in shares)	26,114
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	4 years 9 months 15 days
Exercisable Number of Shares (in shares)	26,114
Weighted- Average Remaining Contractual Life, Exercisable	4 years 9 months 15 days
Exercise Price Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.64	8.64
Outstanding Number of Shares (in shares)	8,800
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 6 months 22 days
Exercisable Number of Shares (in shares)	0
Weighted- Average Remaining Contractual Life, Exercisable	0 years
Exercise Price Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.65	8.65
Outstanding Number of Shares (in shares)	169,000
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 1 month 17 days
Exercisable Number of Shares (in shares)	8,800
Weighted- Average Remaining Contractual Life, Exercisable	3 years 8 months 23 days
Exercise Price Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.73	8.73
Outstanding Number of Shares (in shares)	9,000
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	3 years 1 month 13 days
Exercisable Number of Shares (in shares)	4,000
Weighted- Average Remaining Contractual Life, Exercisable	2 years 7 months 28 days
Exercise Price Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.76	8.76
Outstanding Number of Shares (in shares)	429,198
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	8 years 18 days
Exercisable Number of Shares (in shares)	93,454
Weighted- Average Remaining Contractual Life, Exercisable	3 years 10 months 2 days
Exercise Price Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.86
Outstanding Number of Shares (in shares)	4,941
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 6 months
Exercisable Number of Shares (in shares)	4,941
Weighted- Average Remaining Contractual Life, Exercisable	9 years 6 months
Exercise Price Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 9.64	9.64
Outstanding Number of Shares (in shares)	455,069
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	4 years 5 months 5 days
Exercisable Number of Shares (in shares)	450,864
Weighted- Average Remaining Contractual Life, Exercisable	4 years 4 months 21 days
Exercise Price Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 9.96
Outstanding Number of Shares (in shares)	9,326
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	7 years 7 days
Exercisable Number of Shares (in shares)	9,326
Weighted- Average Remaining Contractual Life, Exercisable	7 years 7 days
Exercise Price Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 10	10
Outstanding Number of Shares (in shares)	8,316
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	9 years 1 month 28 days
Exercisable Number of Shares (in shares)	486
Weighted- Average Remaining Contractual Life, Exercisable	9 years 1 month 28 days
Exercise Price Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 10.81	$ 10.81
Outstanding Number of Shares (in shares)	17,190
Weighted- Average Remaining Contractual Life, Vested or Expected to Vest	8 years 11 months 5 days
Exercisable Number of Shares (in shares)	17,190
Weighted- Average Remaining Contractual Life, Exercisable	8 years 11 months 5 days

Stock-based Compensation - Unv

Stock-based Compensation - Unvested Share-based Compensation, by Exercise Price (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Unvested Shares (in shares)	744,179	422,407
Stock option compensation not yet recognized	$ 2,867	$ 2,683
Share based compensation cost recognition period	3 years 1 month 6 days	3 years 2 months 12 days
Intrinsic value of options exercised		$ 11
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.53	$ 6.53
Number of Unvested Shares (in shares)	100,000	0
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.63	$ 6.63
Number of Unvested Shares (in shares)	21,600	0
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.64	$ 6.64
Number of Unvested Shares (in shares)	60,000	0
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.77	$ 6.77
Number of Unvested Shares (in shares)	0	8,000
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.81	$ 6.81
Number of Unvested Shares (in shares)	17,400	0
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 6.89	$ 6.89
Number of Unvested Shares (in shares)	23,400	0
Exercise Price Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.64	$ 8.64
Number of Unvested Shares (in shares)	8,800	0
Exercise Price Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.65	$ 8.65
Number of Unvested Shares (in shares)	160,200	0
Exercise Price Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.73	$ 8.73
Number of Unvested Shares (in shares)	5,000	31,620
Exercise Price Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 8.76	$ 8.76
Number of Unvested Shares (in shares)	335,744	0
Exercise Price Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 9.64	$ 9.64
Number of Unvested Shares (in shares)	4,205	367,127
Exercise Price Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 10	$ 10
Number of Unvested Shares (in shares)	7,830	0
Exercise Price Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price (in dollars per share)	$ 10.81	$ 10.81
Number of Unvested Shares (in shares)	0	15,660

Stock-based Compensation - Opt

Stock-based Compensation - Option Amendments (Details)

Sep. 24, 2015$ / sharesshares

Jul. 21, 2015

Jun. 04, 2015director$ / sharesshares

Jun. 18, 2014$ / sharesshares

Apr. 29, 2014$ / sharesshares

Jul. 31, 2015

Sep. 30, 2014USD ($)

Jun. 30, 2014USD ($)

Dec. 31, 2015USD ($)$ / sharesshares

Sep. 30, 2015$ / sharesshares

Jul. 23, 2015$ / sharesshares

Jul. 16, 2015$ / sharesshares

Jun. 30, 2015$ / sharesshares

Dec. 31, 2014$ / sharesshares

Sep. 11, 2014$ / shares

Dec. 31, 2013$ / sharesshares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Outstanding stock options (in shares) | shares

1,379,727

615,322

137,610

Exercise price (in dollars per share)

$ 8.71

$ 9.55

$ 25.86

Number of unvested shares (in shares) | shares

744,179

422,407

Number of shares exercisable (in shares) | shares

635,548

192,916

Weighted Average Exercise Price of Options Exercisable, per share (in dollars per share)

$ 9.41

$ 9.44

2014 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted-average incremental fair value (in dollars per share)

$ 3.77

Expected incremental compensation cost | $

$ 1,869,000

2014 Equity Incentive Plan [Member] | Services Business [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Outstanding stock options (in shares) | shares

37,517

Exercise price (in dollars per share)

$ 9.62

Number of unvested shares (in shares) | shares

23,052

Weighted average exercise price (in dollars per share)

$ 9.61

2014 Equity Incentive Plan [Member] | Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

36 months

Number of directors who resigned | director

3

Outstanding stock options (in shares) | shares

12,280

48,283

Exercise price (in dollars per share)

$ 8.64

$ 9.01

Number of unvested shares (in shares) | shares

8,800

Weighted average exercise price (in dollars per share)

$ 8.65

2014 Equity Incentive Plan [Member] | Director [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

36 months

2014 Equity Incentive Plan [Member] | Director [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

2014 Equity Incentive Plan [Member] | June 2015 Terminated Employees [Member] | Services Business [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Outstanding stock options (in shares) | shares

17,715

Exercise price (in dollars per share)

$ 9.64

Number of unvested shares (in shares) | shares

8,331

Weighted average exercise price (in dollars per share)

$ 9.64

2014 Equity Incentive Plan [Member] | Chief Financial Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

36 months

Outstanding stock options (in shares) | shares

74,490

Exercise price (in dollars per share)

$ 9.53

Number of unvested shares (in shares) | shares

50,814

Weighted average exercise price (in dollars per share)

$ 9.49

2014 Equity Incentive Plan [Member] | Non-executive Employee [Member] | Retention Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Outstanding stock options (in shares) | shares

96,014

Exercise price (in dollars per share)

$ 9.31

Number of unvested shares (in shares) | shares

64,279

Weighted average exercise price (in dollars per share)

$ 9.20

Compensatory Arrangement with Executive Officer [Member] | President [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Post employment options exercise period

48 months

Number of unvested shares (in shares) | shares

183,268

Number of shares exercisable (in shares) | shares

84,613

Weighted Average Exercise Price of Options Exercisable, per share (in dollars per share)

$ 9.61

Nonvested options weighted average grant date fair value (in dollars per share)

$ 9.41

2009 Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price (in dollars per share)

$ 41.87

$ 54.87

Additional compensation cost | $

$ 293,000

Options to purchase shares of common stock, for which the exercise price was lowered to the IPO price (in shares) | shares

110,346

53,404

Modified exercise price (in dollars per share)

$ 9.64

$ 10

Exercise price of options, lower range (in dollars per share)

20.40

20.40

Exercise price of options, upper range (in dollars per share)

61.20

$ 61.20

Fair value of options outstanding, post modification

3.08

Fair value of options outstanding, pre modification

5.87

2009 Stock Option Plan [Member] | Scenario, Previously Reported [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Additional compensation cost | $

130,000

1999 Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price (in dollars per share)

$ 21.50

Additional compensation cost | $

$ 225,000

$ 0

Options to purchase shares of common stock, for which the exercise price was lowered to the IPO price (in shares) | shares

73,087

Exercise price of options, lower range (in dollars per share)

$ 20.40

Exercise price of options, upper range (in dollars per share)

$ 25.50

Fair value of options outstanding, post modification

$ 0.78

Fair value of options outstanding, pre modification

$ 3.78

Stock-based Compensation - 201

Stock-based Compensation - 2014 Employee Stock Purchase Plan (Details) - shares	1 Months Ended	12 Months Ended
	Feb. 28, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued through employee stock purchase plan (in shares)		16,874	10,048
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issuable period	10 years
Common stock outstanding percentage	0.80%
Employee stock purchase plan, number of shares, which might be added to common stock outstanding (in shares)	29,411
Number of shares of common stock for future issuance, board of directors prerogative, increase in period (in shares)	0
Common stock issued through employee stock purchase plan (in shares)		16,874	10,048
Shares available for grant, increase over period (in shares)		29,411
For possible future issuance under stock option plan (in shares)		50,283	37,746
2014 Employee Stock Purchase Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
For possible future issuance under employee stock purchase plan (in shares)	47,794

Stock-based Compensation - Com

Stock-based Compensation - Compensation Cost (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	$ 3,023,000	$ 1,201,000
Tax benefit from compensation expense	0	0
Cash received from option exercised	$ 0	$ 9,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense Related to Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 3,023	$ 1,201
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	300	394
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	2,515	648
Discontinued Operations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense related to stock options	$ 208	$ 159

Income Taxes - Additional Info

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating Loss Carryforwards [Line Items]
Income tax benefit	$ 0	$ (1,166)
Income (Loss) from continuing operations before taxes	(28,338)	(6,769)
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	117,272	81,687
Tax credit carryforward	3,573
State and Local Jurisdiction [Member] | North Carolina [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	117,721	85,790
Tax credit carryforward	255
State and Local Jurisdiction [Member] | Pennsylvania [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforward	$ 0	$ 0

Income Taxes - Income Tax Reco

Income Taxes - Income Tax Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income taxes from continuing operations at statutory rate	$ (9,635)	$ (2,301)
State income taxes	(196)	(471)
Stock warrant derivative liability	0	(3,427)
Stock-based compensation	15	268
R&D tax credits	(1,152)	(320)
Loss on sale of discontinued operations, net of reduction in related valuation allowances	(1,458)	0
Other	127	190
Increase (decrease) in valuation allowance	12,553	5,275
Income Tax Expense	$ 0	$ (1,166)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Income taxes at statutory rate, percent of pretax income	34.00%	34.00%
State income taxes, percent of pretax income	0.70%	7.00%
Stock warrant derivative liability, percent of pretax income	0.00%	50.60%
Stock compensation, percent of pretax income	(0.10%)	(4.00%)
R&D tax credits, percent	4.10%	4.70%
Loss on sale of discontinued operations, net of reduction in related valuation allowances	5.10%	0.00%
Other, percent of pretax income	0.50%	2.80%
Increase in valuation allowance, percent of pretax income	(44.30%)	(77.90%)
Effective Income Tax Rate, percent of pretax income	0.00%	17.20%

Income Taxes - Deferred Tax As

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Accrued expenses	$ 783	$ 1,052
Stock-based compensation	1,507	336
Assets of discontinued operations, net of liabilities	0	1,882
Other	19	15
Gross deferred tax assets, current	2,309	3,285
Net operating loss carryforwards	42,358	29,981
Research and development credits	3,836	2,684
Gross deferred tax assets, noncurrent	46,194	32,665
Total deferred tax assets	48,503	35,950
Valuation allowances	(48,503)	(35,950)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Unrecognized Ta

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits	$ 623,000	$ 623,000
Additions for tax positions of current period	0	0
Additions for tax positions of prior periods	0	0
Other	0	0
Unrecognized tax benefits	623,000	$ 623,000
Unrecognized tax benefits that would impact effective tax rate	0
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit	0
Income tax examination, penalties and interest accrued	$ 0

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Computation of Basic and Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Earnings Per Share [Abstract]
Income (loss) from continuing operations	$ (28,338)	$ (5,603)
Deemed dividend for beneficial conversion feature on Series D-2 Preferred	0	(909)
Deemed dividend for antidilution adjustments to convertible preferred stock	0	(214)
Accretion of convertible preferred stock	0	(510)
Loss from continuing operations attributable to common stock - basic	(28,338)	(7,236)
Income from discontinued operations, net of income tax expense, attributable to common stock - basic	(4,285)	1,369
Net loss attributable to common stockholders - basic	(32,623)	(5,867)
Derivative fair value adjustment	0	(10,080)
Loss from continuing operations attributable to common stock - diluted	(28,338)	(17,316)
Income from discontinued operations, net of income tax expense, attributable to common stock - diluted	(4,285)	1,369
Net loss attributable to common stockholders - diluted	$ (32,623)	$ (15,947)
Weighted-average common shares outstanding - basic (in shares)	12,163,559	5,663,311
Incremental shares from assumed exercise of common stock warrants (in shares)	0	273,776
Weighted-average of outstanding common stock - diluted (in shares)	12,163,559	5,937,087
Income (loss) per share, continuing operations, per basic share (in dollars per share)	$ (2.33)	$ (1.28)
Income (loss) per share, discontinued operations, per basic share (in dollars per share)	(0.35)	0.24
Basic (in dollars per share)	(2.68)	(1.04)
Income (loss) per share, continuing operations, per diluted share (in dollars per share)	(2.33)	(2.92)
Income (loss) per share, discontinued operations, per diluted share (in dollars per share)	(0.35)	0.23
Diluted (in dollars per share)	$ (2.68)	$ (2.69)

Net Loss Per Share - Summary 73

Net Loss Per Share - Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Convertible Preferred Stock [Member] | Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	6,149
Convertible Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	131,685
Convertible Preferred Stock [Member] | Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	783,515
Convertible Preferred Stock [Member] | Series C-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	173,213
Convertible Preferred Stock [Member] | Series D-1 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	296,773
Convertible Preferred Stock [Member] | Series D-2 Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	300,549
Warrant [Member] | Series C One Preferred [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	14,033	14,033
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	1,379,727	615,322
Equity Unit Purchase Agreements [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	0	65,401

Related-Party Transactions - Su

Related-Party Transactions - Summary of Transactions with Related Parties (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Revenue	$ 2,140	$ 7,288
Selling, general and administrative expense	$ 0	$ 500

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	May. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
General and administrative expense		$ 0	$ 500
Investor [Member] | Customer Concentration Risk [Member] | Sales [Member]
Related Party Transaction [Line Items]
Percentage of related-party revenue		29.00%	41.00%
Affiliated Entity [Member]
Related Party Transaction [Line Items]
General and administrative expense	$ 500
Sanofi [Member] | Investor [Member]
Related Party Transaction [Line Items]
Ownership percentage of a related party in a customer of the company		100.00%

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)h	Dec. 31, 2014USD ($)
Defined Contribution Plan Disclosure [Line Items]
Work hours per week | h	20
Employer matching percent	50.00%
Maximum percentage of contributions per employee	6.00%
Vesting period	4 years
Contribution amount	$ 183	$ 239
Discontinued Operations [Member]
Defined Contribution Plan Disclosure [Line Items]
Contribution amount	$ 0	$ 176

Compensatory Obligations (Detai

Compensatory Obligations (Details) - USD ($) $ in Thousands	Jul. 21, 2015	Jul. 31, 2015	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 1,012
Accrued restructuring costs			2,639		$ 0
Chief Financial Officer [Member]
Restructuring Cost and Reserve [Line Items]
Cash award granted				$ 138
Deferred compensation payable				179
Accrued restructuring costs			26	335
President [Member]
Restructuring Cost and Reserve [Line Items]
Cash award granted	$ 100
Deferred compensation payable	900
Accrued restructuring costs	$ 1,046		502
Severance costs, payment period	12 months
Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve				999
Remaining severance obligation			$ 763	$ 319
Payments for restructuring		$ 215
Retention compensation payable, maximum		$ 814

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Jul. 16, 2015	May. 04, 2015	Sep. 30, 2015	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charges recorded					$ 586	$ 0
Gain (Loss) on disposal, net of associated transaction costs			$ (73)
Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charges recorded					1,350	0
Gain (Loss) on disposal, net of associated transaction costs	$ (73)				(73)	0
Selling costs	$ 764		$ 764		$ 764	$ 764
Fair Value, Measurements, Nonrecurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Service Business assets, fair value		$ 572
Estimate selling costs		778
Fair Value, Measurements, Nonrecurring [Member] | Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment charges recorded		$ 1,350		$ 1,350

Fair Value Measurements - Asset

Fair Value Measurements - Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	$ 46,985	$ 32,243
Interest-bearing Deposits [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	46,935	32,243
Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	50	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	46,985	32,243
Fair Value, Inputs, Level 1 [Member] | Interest-bearing Deposits [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	46,935	32,243
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	50	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	0	0
Fair Value, Inputs, Level 2 [Member] | Interest-bearing Deposits [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	0	0
Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	0	0
Fair Value, Inputs, Level 3 [Member] | Interest-bearing Deposits [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	0	0
Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Fair value of cash equivalents	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Reconciliation of Beginning and Ending Balances for Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Dec. 31, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 12,237	$ 12,237
Issuance of warrants		544
Excess of fair value of warrants over proceeds	$ 362	362
Adjustment to fair value		(10,442)
Reclassification to additional paid-in capital upon exercise of warrants		(2,701)
Ending balance		$ 0

Significant Agreements (Details

Significant Agreements (Details) - USD ($) $ in Thousands	Oct. 29, 2014	Dec. 31, 2014	Nov. 30, 2014	Jan. 31, 2014	Dec. 31, 2013	Aug. 31, 2013	Dec. 31, 2014	Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Deferred revenue recognition period				48 months		70 months
Elanco Licensing Agreement [Member] | Licensing Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from collaborators					$ 500
Sales based payments					$ 15,000
Deferred revenue recognition period					4 years
Annual service fee, first term					$ 2,750
Annual service fee, period of first term					2 years
Annual service fee, second term					$ 3,000
Annual service fee, period of second term					2 years
Development milestone payment for each compound developed					$ 1,500
Development milestone payment for first regulatory approved product					2,000
Elanco Licensing Agreement [Member] | Licensing Agreement [Member] | United States [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales based payments					4,000
Elanco Licensing Agreement [Member] | Licensing Agreement [Member] | European Union [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Sales based payments					$ 1,500
Waterstone Licensing Agreement [Member] | Licensing Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payment for first product registration			$ 4,000
Option exercise period	18 months
Upfront payment			1,000
Additional upfront payment			$ 500
Licenses Revenue							$ 1,000
Merial Research Services Agreement [Member] | Merial [Member] | Investor [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Term of contract to perform research for others		2 years
Compensation receivable from research for others								$ 7,900
Term of contract to perform research for others, option to extend		1 year
Collaborative Arrangement [Member] | R-Pharm Collaboration Arrangement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Proceeds from collaborators						$ 1,500
Milestone payment for first product registration						3,000
Sales based payments						$ 15,000
Deferred revenue recognition period						70 months

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) $ in Thousands	Jul. 21, 2015USD ($)	Jul. 17, 2015USD ($)	May. 04, 2015USD ($)	Jul. 31, 2015$ / h	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Jul. 16, 2015USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges recorded						$ 586	$ 0
Consideration in escrow						500	0
Research and development						$ 16,440	8,287
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Period of continuing involvement after disposal						6 months
Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges recorded						$ 1,350	$ 0
Aggregate purchase price	$ 3,875
Working capital adjustment	824
Consideration in escrow	$ 500							$ 500
Consideration held in escrow, period held in escrow	12 months
Net cash consideration received at closing	$ 2,549							$ 2,549
Fair Value, Measurements, Nonrecurring [Member] | Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment charges recorded			$ 1,350		$ 1,350
Minimum [Member] | Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employee hourly rate (in dollars per hour) | $ / h				100
Maximum [Member] | Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Employee hourly rate (in dollars per hour) | $ / h				200
Research and Development Arrangement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Contract initial term		18 months
Recorded unconditional purchase obligation		$ 3,300
Continuing Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Research and development						$ 1,602

Discontinued Operations - Proce

Discontinued Operations - Proceeds from and Carrying Amount of Assets from the Sale of the Services Business (Details) - USD ($) $ in Thousands	Jul. 16, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Jul. 21, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration in escrow			$ 500	$ 0
Property and equipment, net			0	4,835
Less: Impairment charge recognized upon classification as held for sale			1,350
Less: Loss on disposal		$ 73
Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net cash consideration received at closing	$ 2,549				$ 2,549
Consideration in escrow	500				$ 500
Total consideration	3,049
Less: selling costs	764	$ 764	764	764
Proceeds from sale, net of selling costs	2,285
Accounts and unbilled receivables, net	1,470
Prepaid expenses and other current assets	713
Property and equipment, net	4,900
Other assets	59
Assets of Services Business, net	7,142
Accounts payable and accrued expenses	616
Deferred revenue	1,657
Deferred rent	1,161
Liabilities related to assets of the Services Business	3,434
Assets of the Services Business, net of liabilities	3,708
Less: Impairment charge recognized upon classification as held for sale	1,350
Less: Loss on disposal	73		$ 73	0
Assets of the Services Business, net of liabilities and impairment charges	$ 2,285
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts and unbilled receivables, net				1,501
Prepaid expenses and other current assets				289
Property and equipment, net				4,835
Other assets				76
Assets of Services Business, net				6,701
Accounts payable and accrued expenses				681
Deferred revenue				445
Deferred rent				1,294
Liabilities related to assets of the Services Business				$ 2,420

Discontinued Operations - Reven

Discontinued Operations - Revenue, Expense, Gain, and Losses Attributable to Discontinued Operations (Details) (Details) - USD ($) $ in Thousands	Jul. 16, 2015	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue			$ 7,408	$ 17,768
Impairment charge from classification of assets as held for sale			(586)	0
Gain (Loss) on disposal, net of associated transaction costs		$ (73)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest			(4,285)	1,369
Services Business [Member] | Discontinued Operations, Disposed of by Sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total revenue			7,408	17,768
Cost of revenue			(7,296)	(15,446)
Research and development			(860)	0
Selling, general, and administrative			0	48
Gain on insurance recovery			0	165
Severance and exit costs			(2,114)	0
Impairment charge from classification of assets as held for sale			(1,350)	0
Gain (Loss) on disposal, net of associated transaction costs	$ (73)		(73)	0
Income tax expense			0	(1,166)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest			(4,285)	1,369
Selling costs	$ 764	$ 764	$ 764	$ 764

Discontinued Operations - Depre

Discontinued Operations - Depreciation, Capital Expenditures, and Significant Operating and Investing Non-Cash Items Related to Discontinued Operations (Details) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from insurance recovery		$ 0	$ 216
Gain on insurance recovery	$ (165)	0	(165)
Stock-based compensation		3,023	1,201
Changes in deferred rent		(108)	(187)
Impairment of fixed asset		0	51
Services Business [Member] | Discontinued Operations, Held-for-sale [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation expense		391	1,132
Purchases of property and equipment		(547)	(704)
Proceeds from insurance recovery		0	216
Gain on insurance recovery		0	(165)
Stock-based compensation		208	159
Changes in deferred rent		(133)	(187)
Equipment purchases in accounts payable and accrued expenses		0	34
Impairment of fixed asset		$ 0	$ 51

Subsequent Events (Details)

Subsequent Events (Details) - shares	Jan. 01, 2016	Feb. 25, 2015	Jan. 01, 2015	Jun. 18, 2014
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of the Company's common stock that may be issued (in shares)	556,223	510,726	340,484	351,653
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of shares of the Company's common stock that may be issued (in shares)	29,411